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Abstract 
Gap junctions (GJ) are intercellular channels connecting adjacent cells, allowing small 
molecules to transport between cells, thereby maintaining all homeostasis. Loss of gap junctional 
intercellular communication (GJIC) and/or connexins, the gap junction proteins, is a hallmark of 
cancer. Restoration of GJIC and/or increase of connexin expression have been related to the 
reduction of tumorigenesis. Connexins have been reported as tumor suppressors due to both 
GJIC-independent and -dependent mechanisms. Therefore, development of effective agents or 
methods to enhance GJIC and restore connexin expression in cancer cells is a new strategy in 
cancer treatment. PQ1, 6-Methoxy-8-[(3-aminopropyl)amino]-4-methyl-5-(3-trifluoromethyl-
phenyloxy)quinoline, has been demonstrated to increase GJIC, restore connexin expression, and 
exert anti-cancer effects on T47D breast cancer cells. Studies of apoptotic pathways showed that 
PQ1 activated both extrinsic and intrinsic apoptotic pathways, indicating that PQ1 exerts its anti-
cancer effects via a GJIC-independent mechanism through the induction of apoptosis. 
Combinational treatment of PQ1 and cisplatin showed that PQ1 counteracted cisplatin-induced 
inhibition of GJIC and reduction of connexin expression, thereby increasing the efficacy of 
cisplatin in T47D cancer cells via a GJIC-dependent mechanism. Further studies of drug 
distribution and toxicity revealed that administration of PQ1 by oral gavage can be achieved with 
low toxicity to normal vital organs. All the results suggest that PQ1, a gap junction enhancer, can 
function as an anti-cancer agent and potentiate the efficacy of antineoplastic drugs via both 
GJIC-independent and -dependent pathways.  
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Chapter 1 - Review of Literature 
1.1 Gap Junctions and Connexins 
Gap junctions are intercellular channels connecting adjacent cells, allowing small 
molecules of less than 1.2 kDa in size to transport between cells. Gap junctions are 
formed by the gap junction protein known as connexins. Six connexins oligomerize into a 
hexameric structure known as connexon. Connexon docks with another connexon from 
the adjacent cell to form a gap junction. Gap junctions have been found in nearly all 
animal organs and tissues.  In normal cells and tissues, gap junctions play an important 
role in controlling cell growth, regulating cell differentiation, and maintaining 
homeostasis. 
 1.1.1 Nomenclature and Distribution of Connexins 
Connexins are found only in vertebrates. Recently, the screening of the mouse and 
human genomic databases has revealed 21 human and 20 mouse connexin genes, each 
encoding a protein [1-4]. Two systems have been used for the connexin nomenclature. 
The most widely used nomenclature system is based on the predicted molecular mass of 
connexin polypeptide [5]. For example, connexin 43 (Cx43) is a connexin with a 
predicted mass of 43 kDa. The other system, the Greek nomenclature system, is based on 
evolutionary considerations [6]. In this system, connexins are divided into subgroups (α, 
β, γ or δ) with respect to a combination of gene structure, overall sequence homology, 
and matching of specific sequence motifs [7], such as α1 represents for Cx43, β1 
represents for connexin 32 (Cx32), and so on. Connexins have a near-ubiquitous 
distribution in the tissues of vertebrates. However, different connexins have been 
observed in different tissues, indicating the tissue specific expression of connexins [1]. 
The connexin genes, the nomenclature of connexins based on two systems, and the 
representative tissues in human are shown in Table 1.  
 
Gene 
Molecular Mass 
Nomenclature 
Greek Letter 
Nomenclature 
Representative 
Tissues/Organs 
2 
 
GJA1 Cx43 α1 Heart, skin, breast 
GJA3 Cx46 α3 Lens 
GJA4 Cx37 α4 
Blood vessels, 
endothelium 
GJA5 Cx40 α5 Heart, endothelium 
GJA6 
(GJA6P) 
Cx33 α6 Pseudogene in humans 
GJA8 Cx50 α8 Lens 
GJA10 Cx59 α9[8] Lens (retina)[9] 
GJA10 Cx62 α10 Lens (retina)[9], ovary 
GJB1 Cx32 β1 Liver, brain 
GJB2 Cx26 β2 
Liver, breast, Cochlea, 
skin 
GJB3 Cx31 β3 Skin, placenta 
GJB4 Cx30.3 β5 Thymus, Skin 
GJB5 Cx31.1 β4 Skin 
3 
 
GJB6 Cx30 β6 Skin, cochlea, brain 
GJB7 Cx25 β7[8] N.D. 
GJC1/GJA7 Cx45 α7 or γ 
Pancreas, small 
intestine 
GJC2/GJA12 Cx47 γ Oligodendrocytes 
GJC3 Cx30.2 γ Ear 
GJD2/GJA9 Cx36 α9 or γ Pancreas, neurons 
GJD3/GJC1 Cx31.9 β 
Liver, spleen, kidney, 
heart, colon 
GJD4 Cx39 α2 Developing muscle 
GJD4 Cx40.1 δ N.D. 
GJE1 Cx23 δ5[8] N.D. 
GJE1 Cx29 δ Brain 
N.D.= Not determined 
Table 1. Summary of published human connexin genes, connexin nomenclatures, 
and representative organs  
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 1.1.2 Structures of Connexins and Gap Junctions 
Examination of amino acid sequences and the locations of different domains 
revealed the structure of connexins [10-13]. The members of connexin family usually 
weigh between 26 and 60 kDa with an average length of 380 amino acids. Despite the 
variations in weight and length, several features of connexins are common to all. Each 
connexin has four hydrophobic transmembrane domains (M1- M4) (Figure 1.1). Studies 
of Cx43 showed that the transmembrane domains are α-helical, on the basis of a 7 Å 
structure [14]. Two loops, between M1 and M2, as well as M3 and M4, are accessible 
from extracellular side [12]. A hydrophilic loop between M2 and M3, the carboxy-
domain (C-terminus) and the amino-domain (N-terminus) are accessible from the 
cytoplasmic side [15]. The conserved regions are located in transmembrane domains and 
extracellular loops [3]. The length of the C-terminus varies among connexins, and is 
responsible for the molecular weight of the connexin. The C-terminus contains several 
sites related to connexin phosphorylation, chemical gating, and protein binding [16-18].  
 
 
 
Figure 1.1 Structure of connexin.  
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The cylinders represent transmembrane domains (M1- M4). The loops between the first 
and second, as well as the third and fourth, transmembrane domains are predicted to be 
extracellular (E1 and E2, respectively). Both the C and N cytoplasmic termini are shown 
in the figure.  
 
Connexins oligomerize into hexamers, the connexons. After formation, connexon 
stays at plasma membrane or docks with another connexon from the adjacent cell to form 
a complete gap junction channel [19]. The two extracellular loops (E1 and E2) are 
considered to be involved in the docking of connexons. In each of the extracellular loops, 
a set of three cysteine residues exists with high reserved order (except for Cx31): [C-X6-
C-X3-C] for the first loop and [C-X5-C-X5-C] for the second loop. Opposing cysteines in 
both loops were reported to form disulfide-bridges enabling two connexons to dock with 
each other [7]. Connexons can be formed with uniform connexins (homomeric) or 
differing connexins (heteromeric) (Figure 1.2). The gap junctions channels contain two 
identical connexons are called homotypic, whereas gap junctions with differing 
connexons are called heterotypic (Figure 1.2). Based on different combinations, gap 
junctions show great variations of channel subtypes. Co-expressions of two compatible 
connexins in the same cells make it possible to assemble heteromeric connexons. Many 
heteromeric connexons have been reported in different organs. Cx26/Cx32 connexons 
have been shown to exist in the liver [20], Cx26/Cx30 connexons in the cochlea[21], 
Cx46/Cx50 connexons in the lens [22], and Cx43/Cx45 connexons in the myocardium 
[23, 24]. However, not all co-expressed connexins can form heteromeric connexons. For 
example, Cx26 is able to co-oligomerize with Cx32 but unable to co-oligomerize with 
Cx43 [20, 25]. The imcompatibility between connexins is suggested to be related to the 
second extracellular domain (E2) [26, 27] and tempers the diversities of gap junction 
channels.  
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Figure 1.2 Possible arrangements of connexons and gap junctions. 
Connexons are composed of six identical connexin subunits (homomeric) or different 
species of connexins (heteromeric). Connexons dock with each other to form gap 
junction channels. Gap junction channels formed with identical connexons are called 
homotypic, while those with different connexons are called heterotypic. Connexins are 
indicated by cylinders (red and blue). 
 
 1.1.3 Regulation Pathways of Connexins 
 1.1.3.1 Biosynthesis of Connexin 
 1.1.3.1.1 Connexin Genes 
Some connexin genes are clustered together within the genome [28]. Human 
chromosome 1 codes for eight connexins, chromosome 6 for four connexins, 
chromosome 13 for 3 connexins, chromosome 17 for two connexins, and chromosomes 
7, 10, 15, and the X chromosome for one connexin each [29]. The general structure of 
connexin genes is very simple. The gene is composed of a separate 5’-untranslated region 
(5’-UTR) which is designated as exon 1, as well as an exon 2 which contains complete 
protein coding sequence and the 3’-untranslated region (3’-UTR) (Figure 1.3 A) [29]. 
Subsequently, exceptions from the initial structure have been described. For example, 
GJB1 (Cx32) has multiple 5’-UTR exons that are spliced in an alternate manner due to 
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transcription from tissue-specific promoters (Figure 1.3 B) [29]. GJC1 (Cx45) has three 
exons, including two 5’-UTR exons with one coding exon. GJC1 transcripts can be 
differentially spliced so that 5’-UTR can be generated from exon 1 and 2 or only from 
exon 2 after transcription driven from a single promoter (Figure 1.3 C) [29]. Additionally, 
in some connexin genes, such as GJD2 (Cx36) and GJE1 (Cx23), the coding region can 
be interrupted by introns (Figure 1.3 D) [29].  
 1.1.3.1.2 Gene Transcription of Connexin 
The transcription of connexin DNAs is regulated by a variety of transcription 
factors, biological substances, and signal transduction pathways, which are cell type-
independent (ubiquitous) or –dependent. The investigations of all factors that regulate 
expression of connexin genes have been reviewed previously [30]. In most connexin 
genes, the basal promoter P1 is located ≤ 300 bp upstream from the transcriptional 
initiation site in exon 1. Within this region, binding sites for transcription factors have 
been identified in several connexin genes. For instance, it contains binding sites for cell 
type-independent transcription factors, including TATA box-binding protein, Sp1/Sp3 
and AP-1, as well as for cell type-dependent factors, containing cardiac-specific 
transcription factors (Nkx2-5, GATA4, Tbx5) and HNF-1 [30]. Binding of these factors 
is not only important for basal expression of connexins, but also important for large 
changes in expression. In addition to the transcription factors, regulation of connexin 
transcription is related to many biological substances and signal transduction pathways. 
For example, cyclic adenosine monophosphate (cAMP) and retinoids have been reported 
to active connexin expression [31-33]. Over-expressions of Wnt1 and H-Ras increase 
expression of Cx43 mRNA and protein, indicating that Wnt pathway and Ras-Raf-MAPK 
pathway are involved in the regulation of Cx43 expression [31, 34].  
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Figure 1.3 Structure of the connexin genes. 
Diagrams show the structures of different connexin genes with the noncoding regions 
(dark blue boxes) and coding regions (light blue boxes). The variations occur in the 5’-
UTR. A. The general structure of connexin gene contained only one 5’-UTR exon. B. 
Some connexin genes contain two or more 5’-UTR exons (1A and 1B) that are 
alternatively utilized due to transcription from tissue-specific promoters. C. Connexin 
genes contain two or more 5’-UTR exons (1 and 2) that may be present with the coding 
exon (3) in the mature mRNA or that may be alternatively spliced to generate multiple 
mRNA variants. For these connexin genes, multiple mRNAs can be generated after 
transcription driven from a single promoter. D. In a few connexin genes, the coding 
region is interrupted by an intron.  
 1.1.3.1.3 Translation of Connexin 
After transcription, the connexin protein is synthesized by translation in the 
ribosomes that are bound to the endoplasmic reticulum (ER) membrane. The encoded 
hydrophobic domains are recognized by a signal recognition particle (SRP) to form the 
SRP/ribosome/nascent-polypeptide-chain/mRNA complex [35]. The complex dock to a 
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protein-channel in the ER membrane which allows the translation of the nascent chain to 
proceed until polypeptide is synthesized [36]. Once complete, connexins are translocated 
from the hydrophilic channel lumen of the translocon to the hydrophobic ER membrane 
environment [37]. The charged residues within the hydrophobic transmembrane regions 
of connexins might be shielded from the hydrophobic bilayer environment through 
oligomerization.  
Although connexin gene expression is considered to be dominantly regulated at 
the transcriptional level, many studies found that alternative regulation at the translational 
level could be in place as well [38]. It has been reported that in addition to the Cap-
dependent translation using the 5’-Cap recognition site, some mRNAs containing internal 
ribosome entry site (IRES) are translated through the Cap-independent translation in cells 
[39, 40]. IRESs have been identified in the 5’-UTRs of some connexin genes, including 
Cx43, Cx32, and Cx26 [41-43], highlighting the potential role of Cap-independent 
translation of connexins especially under the conditions when Cap-dependent translation 
is suppressed. The IRES-mediated translation makes it possible to regulate connexin 
expression at the translational level. For example, Lahlou et al. reported that the existence 
of IRES in Cx26 mRNA permits connexin expression in density-inhibited or 
differentiated cells, where Cap-dependent translation is generally reduced [43]. They also 
found that Cx26 expression is increased at the level of translation in density inhibited 
human pancreatic cells, and the increased translation is not sensitive to rapamycin, an 
inhibitor of Cap-dependent translation, suggesting that the IRES-dependent synthesis is 
an important mechanism of the endogenous expression of Cx26 [43]. In addition to the 
IRES-mediated translational control, regulation of connexin expression through short 
upstream open reading frames (uORFs), which are located between 5’ end of the mRNA 
and the beginning of the main ORF is another type of translational control. The uORF on 
an mRNA generally decreases translation of the downstream genes. uORFs have been 
identified in mRNAs of Xenopus laevis Cx41 as well as mouse Cx31, Cx45, Cx46, and 
Cx47 [44, 45]. Meijer et al. reported that mutation of each of three uAUGs into AAG 
codons of Xenopus laevis Cx41 significantly enhanced translation compared to the wild-
type Cx41 5’-UTR, indicating that the three uORFs play an important role in the 
regulation of Cx41 expression [44]. Pfeifer et al. found that among various mouse Cx43 
10 
 
transcripts, the Cx43 5’-UTRs lacking uAUG have higher translation efficiencies than 
those with uAUGs.  
 1.1.3.1.4 Connexin Assembly and Gap Junction Formation 
The newly synthesized polypeptides of connexins are cotranslationally inserted 
into the ER membranes and transported via the Golgi apparatus and the trans-Golgi 
network to the plasma membrane [46]. During this process, connexin peptides are 
posttranslationally modified and oligomerized into connexons. For example, pulse-chase 
studies show that Cx43 is initially synthesized as a 40 to 42 kDa polypeptide which is 
subsequently posttranslationally modified by phosphorylation of serine residues in a 
serine-rich sequence near the carboxy terminus [47, 48]. The phosphorylation occurs 
soon after translation, even before the Cx43 exit from the Golgi apparatus [49, 50].  
Six connexins oligomerize into one connexon before they transport to the plasma 
membrane. The intracellular location where connexins assemble into connexons is 
connexin-specific. Das Sarma et al. provided evidence for the assembly of Cx32 in the 
ER [51]. Musil and Goodenough reported that the assembly of Cx43 occurs after exit 
from the ER, probably in the trans-Golgi network [52]. Ahmad and Evans demonstrated 
that Cx26 hemichannels are integrated directly into plasma membranes in a 
posttranslational manner [53]. For the heteromeric connexons, Diaz et al. provided 
evidence for the assembly of Cx26 and Cx32 in Golgi membranes, while the oligomeric 
intermediates of Cx26 are in the ER-Golgi-intermediate subcellular fraction [54]. In the 
cells expressing two connexins, it is possible to form either homomeric connexons or 
heteromeric connexons or both. Not any connexins are compatible to form heteromeric 
connexons. Until now, all reported heteromeric connexons are composed of two members 
of the same subgroup. For example, Cx46 hetero-oligomerize with Cx50 (all α-group) 
[22], Cx32 hetero-oligomerize with Cx26 (all β-group) [55], and Cx43 hetero-
oligomerize with Cx40, Cx37, and Cx46 (all α-group), but not with Cx32 (β-group) [56-
58]. It is still unclear that how the selective compatibility between different connexins is 
achieved. Results of co-immunoprecipitation of full-length and truncated Cx43, Cx32, 
and Cx26 polypeptides indicated that hetero-oligomerization might be based on intrinsic 
signals [59, 60]. The signals that allow connexins isoforms to recognize each other might 
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be located in the C-terminus, while the signals that regulates subunit compatibility might 
be located in the N-terminus of the connexin polypeptides. Recent studies using the 
CLUSTAL W algorithm of the OMIGA sequence analysis package suggested that the N-
terminal amino-acid residues at position 12/13 are involved in the oligomerization 
compatibility of α and β connexins [61].  
The trafficking of connexin polypeptides from ER to Golgi is through membrane 
vesicles. Transportation of connexins follows the general intracellular transport route. 
The membrane vesicles containing polypeptides is budded from the ER and fused with 
subsequent intracellular membrane compartments, such as Golgi stacks, [49]. After 
transportation, the membrane vesicles shuttle back to the membrane compartments that 
they originated [62]. The delivery of connexons to plasma membrane has also been 
studied. Lauf et al. reported that Cx43 connexons were delivered in vesicular carriers that 
traveled along microtubules from the Glogi to the plasma membrane [63]. Martin et al. 
reported that Cx26 connexons traffic in a microtubule independent pathway [64]. The 
observations of very short distance between the locations of ER membranes and plasma 
membrane suggested that connexons might be able to transfer directly into the plasma 
membrane from the ER. In addition to microtubules, intact actin filaments have also been 
reported to be involved in the plasma membrane delivery of Cx26 [65].  
After trafficking, the connexons are ready to insert into the plasma membrane. 
Connexons are inserted into the plasma membrane in a closed configuration [66]. Freeze-
fracture electron microscopic studies showed that the insertion is through fusion of 
particle-bearing cytoplasmic vesicle couriers [67]. Lauf et al. reported that insertion of 
Cx43 connexons in non-polarized HeLa cells were distributed over the entire non-
junctional plasma membrane surface [63]. The results of Fluorescence Recovery After 
Photo-bleaching (FRAP) experiments indicated that the inserted connexons can move 
laterally in the plasma membrane. The connexons are distributed in the plasma membrane 
as single particles, or small groups, but not aggregates.  
After insertion, the connexons stay in the plasma membrane as hemichannels or 
dock with another connexon on the adjacent cell to form double-membrane spanning gap 
junction channels (as described in section 1.1.2). The gap junction channels aggregate to 
form plaques instead of staying as single channels on the plasma membrane, and the 
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plaques keep growing by addition of individual gap junction or fusion of small 
aggregates [68, 69]. The number of individual channels in a single plaque varies from 
less than a dozen to several thousands. The newly synthesized gap junctions are added 
along the outer margins of plaques [63, 70]. When removal of older gap junctions in the 
center of plaques and accrual of newly synthesized gap junctions to the margins of 
plaques reach a balance, the size of the plaques keep constant. The mechanisms of the 
gap junction aggregation into plaques are not completely clear. 1.1.3.2 Gap Junction and 
Connexin Degradation 
The half-life of connexins is very short, ranging from 1 to 5 hours [71-73]. Gap 
junctions cannot be separated into connexons during the internalization [74]. 
Morphological and biochemical studies showed that the entire junctions were internalized 
into one of the adjacent cells via endocytosis, and formed double-membrane vacuoles 
named “annular gap junctions” or “connexosomes” [75, 76]. Following internalization of 
gap junctions, connexins are degraded through lysosomal or proteasomal degradation 
pathways [71]. Many regulations, including phosphorylation and ubiquitination have 
been reported to be involved in the degradation process [77, 78]. 
 1.1.3.2.1 Phosphorylation of Connexins 
All connexin isoforms are phosphoproteins, except Cx26 [79, 80]. Connexin 
phosphorylation plays an important role in multiple steps in the life cycle of gap 
junctions, including connexin biosynthesis, trafficking, assembly, membrane insertion, 
channel gating, internalization, and degradation [1]. Several protein kinases, such as 
mitogen-activated protein kinase (MAPK), protein kinase C (PKC), protein kinase A 
(PKA), cdc2/cyclinB, casein kinase 1, v-src and c-src have been identified to target 
different phosphorylation sites on connexins [81]. Most of the consensus sites for 
phosphorylation on connexins are located in the carboxy terminus. For example, on 
Cx43, the phosphorylation sites are Ser-255, Ser-279, and Ser-282 for MAPK, Ser-368 
and Ser-372 for PKC, and Tyr-247 and Tyr-265 for v-src [82-85].  
Cx43 is the most widely studied connexin. The activation routes of protein 
kinases in Cx43 phosphorylation can be generally divided into three pathways (Figure 
1.4) [16, 82, 85]:  
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1. Epidermal growth factor (EGF) binds to its receptor (EGF-R), which induce the 
dimerization and autophosphorylation of EGF-R. The phosphorylated EGF-R interacts 
with Grb2 adaptor protein and SOS guanine nucleotide exchange protein. Membrane-
localized SOS activates ras from GDP-bound form (p21ras-GDP) to GTP-bound form 
(p21ras-GTP), initiating the phosphorylation of raf-kinase (c-Raf). Phosphorylation of c-
Raf activates MAPK kinase (MEK ½) and MAPK. Active MAPK directly 
phosphorylates Cx43 on serine residues (Ser-255, Ser-279 and Ser-282). Binding of 
lysophosphatidic acid (LPA) to its receptor (LBP) also leads to the activation of ras 
through interaction with a heterotrimeric G-protein (Gi), and initiates activation of c-Raf, 
MEK 1/2, and MAPK.  
2. Other ligands (L) bind to their membrane receptors (R), which activates Gq 
proteins. Activation of Gq proteins induces activation of phospholipase C (PLC), and 
subsequently converts phosphatidylinositol 4,5-bisphosphate (PIP2) to diacylglycerol 
(DAG) and inositol 1,4,5-trisphosphate (IP3). DAG directly activates PKC, while IP3 
activates PKC through induction of Ca2+ release from ER. PKC can directly 
phosphorylate Cx43 on serine residues, or activate MEK ½ and MAPK to phosphorylate 
Cx43.  
3. Expression of v-src tyrosine kinase can also phosphorylate Cx43. The tyrosine 
kinase v-src interacts directly with Cx43 via its SH3 and SH2 domains, and 
phosphorylates Cx43 on two tyrosine residues.  
In general, connexin phosphorylation is not a generic prerequisite for connexin 
degradation as evidenced by the fact that Cx26 is not phosphorylated but still appears to 
be degraded in a short time [86]. However, increasing number of reports provide 
evidence that for some connexins, notably Cx43, phosphorylation may trigger its 
internalization and degradation. It has been reported that phosphorylation is correlated 
with Cx43 internalization when cells exit the G2 phase and entering mitosis. At the onset 
of mitosis, p34cdc2 protein kinase-dependent phosphorylation of Cx43 correlated with 
cells rounding and gap junction internalization into large structures which resemble 
internalized annular junctions  [87, 88]. In addition to p34cdc2 protein kinase, PKC 
activation and EGF-induced MAPK activation have also been shown to be tightly 
associated with Cx43 internalization and eventual degradation. Ruch et al. reported that 
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in WB-F344 rat liver cells, PKC-induced phosphorylation was related to gap junction 
internalization [89]. Lampe found that the PKC activator TPA had a significant inhibition 
of Cx43 assembly in Novikoff cells and caused the Cx43 half-life to decrease from 3.1 to 
2 h [90]. Leithe and Rivedal provided evidence to show that EGF-induced 
phosphorylation of Cx43 in IAR20 rat liver epithelial cells resulted in the increased 
ubiquitination of Cx43 which may act as a signal of Cx43 internalization [91]. Although 
the role of phosphorylation in connexin degradation is still controversial, it is reasonable 
to propose that the internalization of connexins, especially Cx43, is regulated by select 
and specific phosphorylation events. Furthermore, the phosphorylation may also regulate 
the ubiquitination of connexins.  
 
 
Figure 1.4 Schematic presentation of three phosphorylation pathways of Cx43. 
1. Binding of EGF to EGF-R induces the receptor dimerization, autophosphorylation and 
interaction with Grb2 and SOS. Membrane-bound SOS transforms ras from GDP-bound 
form (p21ras-GDP) to GTP-bound form (p21ras-GTP). Binding of LPA to its receptor LBP 
which is coupled to Gi protein also activates ras. After activation, ras phosphorylates c-
Raf and subsequently activates MEK ½ and MAPK. MAPK phosphorylates Cx43 on 
serine residues. 2. Other ligands L bind to their receptors R, which induces activation of 
Gq proteins. Gq proteins activate PLC which subsequently converts PIP2 to DAG and IP3. 
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DAG directly activates PKC, while IP3 induces Ca2+ release from ER which also 
promotes PKC activation. Active PKC phosphorylates Cx43 directly or indirectly 
through activation of MEK ½ and MAPK. 3. Tyrosine kinase v-src interacts directly with 
Cx43 through its SH3 and SH2 domains, and phosphorylates Cx43 on tyrosine residues.  
 1.1.3.2.2 Ubiquitination of Connexins 
Some reports suggest that Cx43 is a substrate for ubiquitination [91, 92]. 
Ubiquitination of  Cx43 is important in regulating Cx43 degradation [78]. Ubiquitination 
of Cx43 occurs at the plasma membrane, indicating that ubiquitin might be involved in 
the internalization and intracellular trafficking of Cx43. Since Laing and Beyer reported 
the involvement of ubiquitin in Cx43 degradation in 1995 [92], many studies have 
provided evidence for the role of ubiquitination in Cx43 degradation. Laing and Beyer 
used the Chinese hamster ovary cell line CHO-ts20 with the expression of a thermolabile 
E1 ubiquitin-activating enzyme. They found that Cx43 was increased when the ubiquitin-
activating enzyme is defective, indicating the involvement of ubiquitin in Cx43 
degradation [92]. They also provided evidence that the ubiquitinated Cx43 is mainly 
degraded via the proteasomal pathway [92]. Subsequent experiments performed by 
Leithe and Rivedal suggested that EGF-induced phosphorylation is a signal for 
conjugation of ubiquitin to Cx43 [91]. The EGF-induced hyperphosphorylation, 
ubiquitination, internalization and degradation of Cx43 were found to be mediated by 
MAPK pathway [91]. By using the 12-O-tetradecanoylphorbol-13-acetate (TPA), a 
tumor-promoting PKC activator, to study the effects of PKC on Cx43 ubiquitination, 
Leithe and Rivedal found that TPA-induced degradation of Cx43 was associated with 
strongly increased ubiquitination of Cx43 [93]. Results of coimmunoprecipitation and 
Western blotting showed that the TPA-induced ubiquitination involved both PKC and 
MAPK pathways [93]. Leykauf et al. reported that in the rat liver epithelial cell line WB-
F344, Cx43 binds to the WW domains of E3 ubiquitin ligase Nedd4 through the PY 
motif, a proline-rich region on the Cx43 C-terminal sequence [94]. Depletion of Nedd4 
by RNA interference caused accumulation of Cx43 gap junctions at the plasma 
membrane, indicating that ubiquitination may play a role in the internalization of Cx43 
[94]. Girao et al. further reported that Nedd4-mediated ubiquitination of Cx43 is required 
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to recruit Eps15, an endocytic adaptor containing ubiquitin-binding domains, through its 
ubiquitin-interacting motif, and targets ubiquitinated Cx43 to the endocytic pathway [95]. 
Based on all the evidence, the degradation pathway of Cx43 can be described: 
Activation of MAPK or PKC phosphorylates Cx43, which subsequently recruits E3 
ubiquitn ligase, such as Nedd4. Nedd4 binds to Cx43 via WW domains and ubiquitinates 
Cx43. In the ubiquitination process, the recruitment of Eps15 is required. After 
ubiquitination, Cx43 is degraded through proteasomal pathway. Nedd4 can also bind to 
Cx43 independently of the Cx43 phosphorylation state. In addition to a ubiquitin-
dependent pathway for Cx43 endocytosis, a ubiquitin-independent pathway exists, in 
which the YXXΦ motif in the Cx43 C terminus is important.  
No direct evidence exists that other connexins are ubiquitinated prior to 
internalization and degradation, except Cx43. Henzl et al. have reported that OCP1 
(organ of Corti protein1) harbors a consensus F-box motif which is a subunit of a SCF E3 
ubiquitin ligase and that OCP1 binds to Cx26 in the Corti [96, 97]. However, further 
studies are needed to determine the role of this interaction in Cx26 trafficking and 
degradation. 
 1.1.3.2.3 Degradation of Connexins 
Both lysosomal and proteasomal degradation pathways have been reported to be 
involved in connexin degradation [98]. The role of lysosomes in degrading connexins is 
prominent. Electron microscopic studies showed that connexosomes are able to fuse 
directly with lysosomes, providing convincing evidence that lysosomes play a critical 
role in connexin degradation [76, 99, 100]. Based on inmmunoelectron microscopic 
experiments, Leithe et al. suggested that internalized Cx43 gap junctions undergo a 
maturation process from double-membrane vacuoles to multivesicular endosomes with a 
single limiting membrane [101]. This transformation is associated with trafficking of 
Cx43 from early endosome to late endosome, prior to lysosomal degradation of Cx43 
[101]. Proteasomal degradation pathway plays a critical role in some cell types as 
evidenced by the fact that lysosomal inhibitors, such as chloroquine, leupeptin, and 
NH4Cl, do not cause as much of an increase in the half-life of Cx43 as proteasomal 
inhibitors [102]. For example, in CHO cells, lysosomal inhibitors have modest effects on 
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the half-life of Cx43 while proteasomal inhibitors are more potent at extending the life of 
connexins [103]. In some cells types, such as MDA-MB-231 breast cancer cell line, both 
lysosome and proteasome play distinct roles in the life cycle of Cx43. Qin et al. 
demonstrated that in MDA-MB-231 cells, secretory Cx43 and internalized gap junctions 
were degraded by lysosomes, while destabilization of phosphorylated gap junctions at the 
plasma membrane were associated with proteasomes [104]. How the cells select the 
degradation pathways of connexins is still not clear. Girao and Perira showed that 
phosphorylation of Cx43 stimulates proteasome-dependent degradation in lens epithelial 
cells [105]. Thomas et al. found a tyrosine-based sorting signal in the C-terminus of Cx43 
that appears to be a prime determinant of Cx43 stability by targeting Cx43 for 
degradation in the endocytic/lysosomal compartment [106].  
 
 
Figure 1.5 The life cycle of a connexin. 
The connexin is synthesized in the ribosomes that are bound to the endoplasmic 
reticulum (ER) membrane and entered the classical secretory pathway. Connexin 
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topology is established in the ER where the protein is observed traversing the membrane 
four times. Connexin transport vesicles bud from exit sites of ER and fuse with the cis 
Golgi network of the Golgi apparatus. Oligomerization of connexins into connexons 
occurs in the ER, Golgi or trans Golgi network (TGN). Mis-folded connexins are 
translocated from ER membranes and degraded by proteasome. In some transformed cells 
with defective protein trafficking characteristics, connexins may be able to enter 
lysosomes for degradation. Closed connexons are delivered by transport vesicles to the 
cell surface with the help of microtubules. Connexon remains closed and diffuse 
throughout the plasma membrane until docking with another connexon in the adjacent 
cell to form a gap junction channel. The docking of connexons is facilitated by cadherin-
based cell adhesion. Connexin binding proteins are proposed to play a role in regulating 
gap junction assembly and function. Gap junctions aggregate into plaques. The gap 
junction plaque is assembled from the outer rim and the inner gap junctions become 
internalized as double-membrane structures termed annular junctions or connexosomes. 
Other mechanisms of gap junction disassembly and internalization using clathrin, 
caveolae and endosomes have not been ruled out. Degradation of gap junctions is 
complex and evidence suggests roles for both proteasomes and lysosomes. Gap-junction-
like membrane fragments have been identified in lysosomes. Connexin phosphorylation 
and ubiquitination have been reported to play important role in the proteasomal-
degradation of Cx43. The life cycle of connexins has a very short life-time, ranging from 
1 to 5 h.  
 
 1.1.4 Functions of Gap Junctions 
 1.1.4.1 Function of Gap Junction Channels 
Gap junctional channels connect the cytoplasm of two cells, and provide a means 
for adjacent cells to exchange small molecules of less than 1.2 kDa, including H2O, ions 
(K+ and Ca2+), second messengers (cAMP, cGMP, and inositol 1,4,5-triphosphate (IP3)), 
and small metabolites (glucose), allowing electrical and biochemical coupling between 
cells [107, 108]. According to the properties of the molecules transported by the gap 
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junctional cell-cell communication, the functions of gap junctions in tissues can be 
categorized as follows: 
1) Rapid exchange critical ionic electrical signals, such as Ca2+, and their 
regulators. By gap junctional communication, waves of Ca2+ ions can move from a 
disturbance point in a field of cells through cells to neighboring cells in order to signal 
the disturbance, so that the regional tissue reaction can occur in coordinated manner 
[109].  
2) Allow the distributions of critical metabolites, such as cAMP, among tissue 
cells. Because all of the cells in a tissue do not possess the same metabolic capacity, gap 
junctional communication can help the cells of lower capacity benefit from those with 
higher capacity [110]. Therefore, gap junction-mediated sharing of essential metabolites 
is beneficial to the tissue as a whole.  
3) Nourish the sick or deprived cells by healthy neighboring cells. When the gap 
junctional intercellular communication is not compromised and the toxicity limit is not 
exceeded, the cell injured is remediated with assistance from healthy neighboring cells, 
so that a tissue can recover after a toxic insult, keeping the homeostasis of the tissue.  
4) Alleviate the harmful effects of xenobiotic chemicals. By dispersing 
xenobiotic molecules from the exposure entrance point into the tissue via gap junctions, 
the local concentration of offending xenobiotics are diluted and easy to be metabolized in 
more cells and in a steady-state fashion. 
5) Eliminate unwanted byproducts. By gap junctional communication, 
byproducts are eliminated from tissue interior cells to the vascular system in a gradient 
fashion for purpose of excretion.  
 1.1.4.2 Function of Hemichannels 
In addition to gap junctional intercellular communication, connexin-forming 
hemichannels function as independent entities between intra- and extracellular milieus, 
which play critical roles in modulating cellular functions. Many functions have been 
reported to be related to hemichannels, including isosmotic cell volume regulation, 
inhibition of the activity of Ca2+-channels and glutamate release in the retina, rescue from 
apoptosis, regulation of glutamate and aspartate release in astrocytes, and differentiation 
20 
 
of teratocarcinama progenitor cells into neuronal and nonneuronal cells [111-116]. 
Hemichannels regulate cellular functions probably by the factors released through the 
open hemichannels. The released factors bind to the receptors on cell surface, which 
accordingly lead to the activation of intracellular signaling pathways and regulation of 
cellular function and physiology through gene transcription, translation, or post-
translation. Recent studies showed that connexin hemichannels release molecules like 
PGE2, ATP and NAD+ in response to stimuli such as mechanical stimulation, lower 
extracellular calcium, lower pH or metabolic inhibition [117]. ATP mediates cochlear 
homeostasis, ischemic preconditioning, and cell cycle through G-protein coupled 
purinergic receptor signaling [117]. PGE2 activates β-catenin, and subsequently induces 
Cx43 transcription [117]. NAD+ mediates cADPR, a factor related to cell cycle 
progression [117]. Detailed signaling pathways associated with hemichannel 
communication are still under investigation.  
 1.2 Gap Junctions and Diseases 
 1.2.1 Overview 
Mutations in connexins and dysregulation of gap junctions are associated with 
many diseases. At present, ten distinct diseases have been linked to gene mutations of 
connexin family members, such as demyelinating neuropathies, various skin disorders, 
cataracts, sensorineural deafness, oculodentodigital dysplasia (ODDD), and so on. The 
first discovered human disease caused by gene mutation in connexin is chromosome-X-
linked Charcot-Marie-3 Tooth disease, a peripheral neuropathy [118]. This disease is 
related to over 270 mutations in Cx32 and clinically manifested by progressive peripheral 
axon demyelination and limb weakness [119-121]. After that, a broad scope of human 
diseases has been reported to be induced by connexin mutations. Up to 40-50% of all 
cases of inherited neurosensory deafness are associated with mutations in the genes 
encoding Cx26, Cx30, Cx31, Cx32 and Cx43 [122]. Pelizaeus-Merzbacher-like disease is 
associated with gene mutations of Cx47 [123]. Skin disorders, including keratitis-
ichthyosis and palmoplantar keratoderma are linked to mutations in Cx26, Cx30, Cx30.3, 
Cx31, and Cx43 [124]. The skin diseases caused by the connexin mutations are always 
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accompanied by other diseases, like deafness, erythrokeratodermia variabilis, hidrotic 
ectodermal dysplasia and Clouston’s syndrome [124]. Congenital cataracts are related to 
mutations of Cx46 and Cx50 in lens [125]. ODDD which is occasionally accompanied by 
palmoplantar keratoderma is associated with Cx43 mutations [126]. Lastly, atrial 
fibrillation is reported to be associated with somatic mutations in Cx40 [127]. The 
connexin-linked diseases and the related connexin mutations are listed in Table 2. 
 
Connexin-linked diseases Gene mutations in connexins 
Peripheral neuropathy (X-linked Charcot-
Marie-Tooth disease) 
Cx32β1 
Deafness 
Cx26β2, Cx30β6, Cx31β3, Cx32β1, and 
Cx43α1 
Skin disorders 
Cx26β2, Cx30β6, Cx31β3, Cx30.3, and 
Cx43 
Cataracts Cx50α8 and Cx46α3 
Oculodentodigital Dysplasia (ODDD) Cx43α1 
Atrial fibrillation Cx40 
Pelizaeus-Merzbacher-like disease Cx47 
Table 2 Connexin-linked diseases and the connexins with related gene mutations 
 
Apart from the connexin-linked disease associated with gene mutations, many 
diseases, termed connexin-dysregulated diseases, are related to changes in connexin 
expression level, assembly state, localization, and deficiency in gap junctional 
intercellular communication. One example of the connexin-dysregulated diseases is 
illustrated by cardiovascular disease which is caused by the changes in the gap junction 
distribution and remodeling. In advanced ischemic disease, the normal distribution of gap 
junctions in the narrow zone consisting of 5 layers of cells bordering healed myocardial 
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infarctions was disrupted with a shift of Cx43-containing spots to the lateral cell borders 
[128]. In a guinea pig model of congestive heart failure, a 37% reduction of Cx43 was 
observed at the congestive heart failure stage [129]. Matsushita et al. found that in rat 
ventricular cells bordering healed infarcts, many of the lateral gap junction plaques have 
no contributions to cell-to-cell communication, suggesting that lateralization of gap 
junctions is a prominent feature of diseased myocardium [130]. Other studies showed that 
protein kinases and phosphatases play an important role in disease state. In myocardial 
ischemia, Cx43 becomes increasingly less phosphorylated, redistributes to the lateral cell 
surfaces and accumulates in intracellular compartments [131]. Later studies by Solan et 
al. revealed that Cx43 phosphorylation at S365 was lost in ischemic hearts, while 
phosphorylation at S368 was increased [132]. Kieken et al. reported that scaffolding to 
Cx43 by ZO-1 is competed by active c-Src binding to ZO-1, leading to Cx43 
relocalization to lateral cell surface and finally result in arrhythmogenesis [133]. All these 
examples reveal that cardiac pathologies are closely related to connexin redistribution 
and remodeling. 
Another important example of connexin-dysregulated diseases is cancer. 
Numerous reports have provided evidence to establish the relationship between connexin 
dysregulation and cancer.  
 1.2.2 Gap Junctions and Cancer 
Cancer is a complicated disease which is caused by multiple different 
mechanisms related to cell differentiation, regulation and growth control. Because gap 
junctional intercellular communication (GJIC) has been associated with control of cell 
growth, development, differentiation and homeostasis, it is supposed that there may be a 
link between cancer and GJIC.  The assumption first originated from Loewenstein and his 
colleagues who found the lack of cell coupling in rat and human hepatoma cells, tumors 
of the thyroid in rodents, and carcinoma of the stomach in humans [134-136]. Based on 
several studies in 1960s, Loewenstein hypothesized that lacking of gap junctions or GJIC 
is a prerequisite to the dysregulation of growth control, and is related to tumorigenesis. 
This hypothesis was formulated and documented into a prescient review in 1979 [137]. 
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Since then, a tremendous accumulation of results have been reported to demonstrate the 
important roles of connexins and GJIC in cancer. 
Through the years, a phenotypically heterogeneous population of neoplastic cells 
generates, forming a tumor. Considering the progression of solid tumors, cancer 
development can be schematically separated into three fundamental stages: growth of the 
primary tumor, invasion, and dissemination (metastasis). These three fundamental stages 
of solid tumor progression are representative of three very different phenotypes of cancer 
cells: deregulated growth (tumor formation), motility (invasive tumor), and interaction 
with both the endothelial barrier of blood or lymphatic vessels and the cells of the 
colonized organs (metastatic tumor). Because of the different phenotypes, it is possible 
that the junctional behavior of cancer cells is different at every stage. For example, 
disruption of intercellular junctions may be necessary for cell detachment and motility 
during cancer invasion, whereas establishment of cell-cell contact between cancer cells 
and endothelial cells would be needed during cancer metastasis. Thus, the role of gap 
junctions might be different depending on the cancer stage.  
 1.2.2.1 Gap Junctions and Primary Tumor Growth 
Over the past four decades, a considerable amount of studies exploring the link 
between gap junctions and tumor growth have reported that gap junctions and/or 
connexins play a tumor suppressing role. Using various tumor cell lines and transgenic 
mouse strains, many kinds of evidence have been provided to support the idea of a tumor 
suppressor function for gap junctions and/or connexins. For example, gap junctions 
and/or connexins are absent or greatly reduced in many primary tumors as well as in cell 
lines that are derived from primary tumors [138-140]. Additionally, it has been known for 
a long time that multiple tumor-promoting agents (such as 12-O-tetradecanoylphorbol-
12-acetate (TPA) and cigarette components) and oncogenes (such as ras, v-mos, neu, src, 
little and large T, and E1A) down-regulate connexin expression and inhibit GJIC in 
cancer cells, whereas antitumor agents (such as retinoic acid and retinol) up-regulate 
GJIC [141-144]. Furthermore, reintroduction of connexins into tumor cells reduces cell 
proliferation and tumor growth, and partially re-differentiates transformed cells [145-
148]. Transfection of connexin 32 cDNA into communication-deficient human 
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hepatocellular carcinoma SKHep1 cells significantly retarded xenograft tumor growth in 
vivo [149]. Differential or subtractive gene profiling, as well as gene knockdown studies, 
also identified connexins as potential tumor suppressors [150, 151]. Lastly, recent studies 
using transgenic and mutant mouse models showed that connexin-knockout mice, as well 
as mice expressing reduced or dominant-negative connexins, have an increased incidence 
of tumor onset when challenged with a carcinogen [152-155]. The maintenance of a full 
complement of connexins is likely to be protective against tumor onset. This might be 
illustrated by the evidence that mice lacking Cx32 are more susceptible to chemical- and 
radiation-induced liver and lung carcinomas [152, 153], as well as the evidence that 
Cx43+/- mice have an increased incidence of chemically induced lung neoplasm [154]. 
Collectively, these studies provide evidence that connexins and/or gap junctions exhibit 
tumor suppressive properties in tumorigenesis. 
The mechanisms by which connexins play a tumor suppressing role in 
tumorigenesis were originally proposed to be GJIC-dependent  [156, 157]. The primary 
role of connexins is linked to the formation of gap junction channels which mediate the 
intercellular exchange of small molecules. Therefore, it is not surprising that the 
mechanism associated with tumor suppressing role of connexins is supposed to be related 
to the specific molecules that are exchanged among healthy cells through GJIC compared 
with the lack of such exchanges in cancer cells without GJIC. This leads to the studies, 
identifying molecules that need to be exchanged for cells to maintain a normal cell cycle 
and inhibit the transformation of cells into invasive cell types. However, so far, few 
molecules have been identified to transport through gap junctions. Among them, some 
molecules are involved in very fundamental and metabolic pathways of the cells, such as 
adenosine diphosphate, and cannot help to understand any putative role of connexins in 
carcinogenesis [158], whereas other molecules play a more informative role. For 
example, the glutathione, a tripeptide, has high permeability through gap junction 
channels. Its antioxidant properties protect cells from reactive oxygen species, thus 
protecting cells from DNA damage, as well as detoxifying carcinogens [159, 160]. In 
addition, the gap junctions transport second messengers, such as cAMP and IP3, 
suggesting that gap junctions are involved in the tissue homeostasis and in the 
intercellular diffusion of hormonal information [161, 162].  
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Studies using inhibitors of GJIC and connexin mutants lacking the ability to form 
gap junction channels suggest that at least in some cases, connexins exhibit the tumor 
suppressing functions through a GJIC-independent pathway [163-166]. For example, 
Moorby and Patel reported that wild-type Cx43 inhibited growth of Neuro2a cells under 
conditions where gap junctions were unable to form [167]. Moreover, the C-terminus of 
Cx43 which could not form gap junctions was as effective as the wild-type in suppressing 
the growth of Neuro2a cells [167]. This study provide direct evidence suggesting that 
growth regulation by Cx43 is independent of gap junction formation in Neuro2a cells. 
The mechanism of GJIC-independent function of connexins remains unknown. Several 
possible mechanisms have been hypothesized. First, the carboxyl terminus of Cx43 
interacts with transcription factors and regulates gene expression. The connexins that 
exhibit cell growth suppression function have been localized to the cytoplasm or nucleus 
and the putative nuclear-targeting sequence encoded within the carboxyl terminus [167, 
168].  Second, the inhibition of cell and tumor growth by connexins could be related to 
the involvement of connexins in the cell cycle regulation. Zhang et al. reported that over-
expression of Cx43 contributed to an accumulation of the lypophosphated retinoblastoma 
(Rb) protein and an increase in the level of cyclin-dependent kinase inhibitor p27 [169]. 
The same group also reported that Cx43 inhibited expression of S phase kinase-
associated protein 2 (skp2), a human F-box protein that promotes the ubiquitination of 
p27 [170]. Both Skp2 and p27 were required for Cx43 to inhibit cell proliferation, 
because Cx43 barely inhibited cell proliferation of Skp2-/- and p27-/-  cells [170]. 
Furthermore, inhibition of skp2 expression was observed by using C-terminal domain of 
Cx43, a truncated Cx43 that cannot form gap junctions, and the inhibitory effect cannot 
disrupted by the coupling inhibitors, indicating the GJIC-independent mechanism of 
Cx43 in the cell cycle [163, 170]. Third, phosphorylation of connexins may be another 
factor associated with the GJIC-independent mechanism. Phosphorylation of Cx43 on 
S262 by protein kinase C (PKC) counteracted the inhibition of HEK-293 cell growth by 
Cx43 through a GJIC-independent pathway [171]. Studies of Cx43 transfection in human 
glioblastoma cell revealed that transfected Cx43 normalized cell phenotype through an 
accumulation of the unphosphorylated Cx43 in the cytoplasm and even in the nucleus 
[172]. Last, the GJIC-independent effect of connexins may be related to the interactions 
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with tumor-suppressing molecules responsible for important signaling pathways. For 
example, Cx43 has been reported to interact with tumor-suppressing molecule, caveolin 1, 
in keratinocytes and suppress tumor growth [173, 174]. Cx43 has also been reported to 
interact with nephroblastoma overexpressed (NOV), a matricellular protein involved in 
cell signaling and communication that has been shown to suppress tumorigenesis [175, 
176].  
 1.2.2.2 Gap Junctions and Cancer Invasion 
The strong non-covalent links between docked connexons affords adhesive 
properties, suggesting that connexins may have effects on cell adhesion and migration 
[177, 178]. In the rat C6 glioma model, the level of Cx43 expression has been shown to 
be related to the mobility capacity of glioma cells. Results of wound healing and 
transwell assays demonstrated that cell migration was increased by the over-expression of 
Cx43 [179]. Lin et al. reported that Cx43 expression induced the morphological 
transformation of glioma cells into an epithelial phenotype, increased the competence of 
glioma cells to aggregate, enhanced the cell adhesivity, and mediated the invasion of 
malignant glioma cells [177]. The use of antibodies specific against the extracellular 
domain of Cx43 reduced cell aggregation in glioma cells and restored the connexin-
deficient phenotype [177]. Further studies by Zhang et al. showed that when co-culture 
Cx43-C6 glioma cells and astrocytes, the astrocytic phenotype was modified [180]. It was 
suggested that this phenotypic transformation of astrocytes may contribute to their 
susceptibility to Cx43-C6 glioma invasion [180]. The acquired migration capacity is 
related to the presence of matrix metalloproteinases (MMP-2 and MMP-9) in culture 
medium from Cx43-C6 glioma cells [181]. Overall, a model using glioma cells provides 
evidence that connexins are associated with cancer cell migration and invasion. 
In skin and prostate cancer cells, cell migration is associated with gap junctions 
and Cx26 expression [182, 183], suggesting that the connexin-mediated migration is not 
cell type or connexin isoform specific. Collectively, although the mechanism is not clear, 
all the studies provide evidence that increase of connexin expression and gap junctions 
can enhance cell migration and invasion in many cancer cell types. There are also some 
exceptions. One of the exceptions is that in Hs578T breast cancer cells, silencing Cx43 
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increased the cell migration capacity [151]. These studies add to the complexity in 
understanding the relationship between connexin expression and cancer cell motility.  
 1.2.2.3 Gap Junctions and Cancer Metastasis 
In addition to the functions of connexins in tumorigenesis, a role for connexins in 
tumor metastasis is also suggested by many studies; however, they are controversial. One 
of the first steps of metastasis is that cancer cells interact with endothelial cells to pass 
through the vascular barrier and transport into lymph or blood flow. In this step, gap 
junction channels may be needed for the invasive cells to interact with endothelial cells. 
Actually, GJIC has been observed between vascular endothelial cells and malignant cells 
from various tumor types, such as glioma, melanoma, and breast cancer cells [184-186]. 
These observations indicate that the connexins and gap junctions, which are frequently 
lost in the primary tumors, may appear at later stage of cancer progression. This has been 
illustrated by the evidence that in mouse skin carcinogenesis, the reduced Cx26 at the 
early stage is restored in tumor metastases in lymph nodes [187]. Same results were also 
observed in breast cancer. During the progression of human breast cancer, Cx26- and 
Cx43-negative primary tumors were found to develop Cx26- and Cx43-positive 
metastases in lymph nodes [188].  
Angiogenesis is a preliminary and crucial step of the metastatic process. The role 
of connexins in angiogenesis remains controversial. Studies using breast cancer cells 
indicate that connexin expression plays a protective role against angiogenesis. For 
example, Shao et al. reported that the decreased expression of Cx43 in Hs578T breast 
cancer cells resulted in decreased levels of thrombospondin-1 (TSP-1, an 
antiangiogenesis molecule) and increased expression of VEGF [151]. Further studies by 
Qin et al. showed that Cx26 down-regulated the expression of connective tissue growth 
factor (CTGF), an angiogenesis-related gene, and increased TSP-1 [189]. These data 
suggest that connexins are function as inhibitors of angiogenesis in breast cancer cells. 
However, studies using glioma cells have a completely different result. Cx43 expression 
in Cx43-transfected T98G human malignant glioma cells has been reported to 
significantly increase tubulogenesis of co-cultured human umbilical vascular endothelial 
cells (HUVECs) [184]. The reason why Cx43 has opposite effects on angiogenesis in 
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breast cancer cells and glioma cells is not clear. However, even if they are contradictory, 
these results provided evidence for the complex functions of connexins in angiogenesis.  
 Cancer metastasis in part is involved in the interactions between metastatic cells 
and the cells of the targeting colonized tissue. Studies exploring cell-to-cell 
communication between MDA-MB-435 breast carcinoma cells and hFOB1.19 human 
osteoblastic cells indicated that gap junctions may play a role in these interactions. 
Kapoor et al. reported that MDA-MB-435 cells formed heterotypic gap junctions with 
osteoblastic cells [190]. This heterotypic GJIC was even quantitatively greater than the 
homotypic communication in bone [190]. Furthermore, the heterotypic GJIC was not 
significantly affected by the transfection of BRMS1, a breast cancer metastasis-
suppressor gene [190]. Further studies are needed to check whether the heterotypic GJIC 
between metastatic cells and cells of the target tissue play a role in the dormancy of 
metastasis. 
  1.2.3 Gap Junctions and Breast Cancer 
Breast cancer is one of the most malignant diseases that threaten the health of 
women all over the world, especially in western countries. It ranks the second leading 
cause of cancer deaths among women in the United States [191]. Mammary development 
is a process with the contributions of many factors. Recent studies showed that gap 
junctions play an important role in the mammary development and breast carcinogenesis.  
 1.2.3.1 Development of Mammary Gland 
Human mammary glands and mouse mammary glands have similar structure, 
except the relative abundance of connective tissue to epithelial cells [192]. This similarity 
as well as the accessibility makes the mouse mammary gland as a good model to study 
the development and differentiation of human mammary glands. Studies showed that 
mammary gland development can be generally divided into four stages [193]. The first 
stage is from birth to puberty. In this stage, the gland is only composed of a rudimentary 
collection of small ducts, and the growth of the rudimentary tree is restricted until 
puberty. The second stage is from puberty to pregnancy. At the onset of puberty, 
systemic hormones induce the ducts to branch and elongate into the surrounding adipose 
tissue. Upon pregnancy, the third stage, full differentiation of the gland induces further 
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ductal branching and proliferation. The alveologenesis, in which lobulo-alveolar milk-
secreting buds sprout at the forefront of the ducts, occurs in this stage. In the mature 
gland, a series of alveoli join up to form a group known as lobules, and each lobule drains 
into openings in the nipple through a common ductal system. The ducts and alveoli are 
lined by single layers of mammary epithelial cells. An outer layer of myoepithelial cell 
surrounds the alveoli and provides contractile strength for milk ejection when the alveolar 
luminal cells secrete milk into the lumen during lactation. The fourth stage is post-
weaning. After weaning, the structure of the glands returns to the pre-pregnancy 
architecture due to the extensive apoptosis and autophagy. The third and fourth stages are 
cyclic with each pregnancy and birth. Figure 1.6 shows all the stages of mammary glands 
development.  
 
Figure 1.6 Scheme of mammary gland development. 
Four stages are included in mammary gland development. Before puberty, the gland 
mainly consists of rudimentary ductal system. On the set of puberty, ductal elongation 
and bifurcation occur. At pregnancy, the gland undergoes alveologenesis and lactogenic 
differentiation, changing the mammary gland to a structure that is suitable for lactation. 
After weaning, during the involution, the gland remodels to regain a pre-pregnancy 
structure.  
 1.2.3.2 Role of Gap Junction in the Development of Mammary Gland 
Many factors contribute to the regulation of mammary gland development and 
differentiation, including systemic hormones and paracrine factors, tight and adherens 
junctions, and gap junctions. Both the function of gap junction channels and connexin 
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expression are regulated throughout the development of mammary gland. The functions 
of gap junctions in mammary development and differentiation are not only related to the 
GJIC, which is important to the cross-talk between cells, but also concerned with the 
signaling cascades regulated by connexin-associated molecules.  
 1.2.3.2.1 Connexin Expression in Mammary Gland 
Up to date, only two connexins, Cx26 and Cx43 were identified in human 
mammary gland [194]. Both the Northern analysis and immunocytochemistry showed the 
expressions of Cx26 and Cx43 in normal mammary epithelial cells [195]. Further studies 
of dye transfer indicated a functional channel formed by connexins between epithelial 
cells [195]. Monaghan et al. reported a localization of Cx43 in myoepithelial cells and a 
predominant expression of Cx26 between the luminal cells of ducts [196]. Cx43 was also 
reported to express in normal human mammary fibroblasts [195].  
Unlike the human mammary gland, in addition to Cx26 and Cx43, another two 
connexins, Cx32 and Cx30, were reported in the mouse mammary gland [197]. In the 
mouse mammary gland, Cx43 channels were identified between myoepithelial cells and 
Cx26 channels were found between luminal cells, which are similar to the locations in 
human mammary cells. However, Cx30 and Cx32 were also reported to express in 
luminal cells, peaking during lactation [194]. In vitro studies showed that Cx32, Cx30 
and Cx26 had abilities to form heteromeric connexons [198].  In the study by Talhouk et 
al., Cx43 was also found to form gap junction between myoepithelial cell and epithelial 
cell at several developmental stages; however, this finding is somewhat controversial 
[197].  
 1.2.3.2.2 Connexin Function in the Stages of Mammary Gland Development 
The expression profiles of various connexins in different stages of mammary 
gland development suggest the possible functions of connexins. For example, Cx43 is 
expressed throughout development, indicating it may play a role in the growth and 
differentiation of myoepithelial cells. Cx43 is down-regulated at mid-pregnancy and 
almost disappears during lactation but is re-expressed after involution [199]. However, 
expressions of Cx26, Cx30, and Cx32 increase throughout pregnancy, peak at the onset 
of lactation, and then decline in involution, suggesting that these connexins may be 
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essential to milk production and/or secretion [197]. To further study the distinct functions 
of connexins and gap junctions in the mouse mammary gland, knockout and transgenic 
mouse models are used. Cx43 knockout mice were lethal; however, the Cx43KI32 mice, 
in which Cx43 was replaced with Cx32, sheds some light on Cx43 function. The 
Cx43KI32 mice had normal mammary gland development and milk production, but had 
impaired milk ejection, indicating that Cx43 played a role in providing contractile force 
to the myoepithelial cells for milk ejection [200]. The mouse model (Gja 1Jrt/+), which has 
an autosomal dominant mutation in Cx43 and is used to mimic the human disease 
oculodentodigital dysplasia (ODDD), also provided a sight to the role of Cx43. In this 
model, Cx43 mutation induced a delay in mammary gland development, a failure in milk 
delivery, but no changes in morphology of the gland, indicating the involvement of Cx43 
in milk ejection. Cx26 knockout mice were lethal too.  However, a conditional knockout 
of Cx26 in the mammary epithelium before puberty led to deficiency in lobuloalveolar 
development and function during lactation, whereas ablation of Cx26 during the 
pregnancy had no effects on alveolar development and function [201]. Similarly, Cx32-
null mice had normal development and function of mammary gland, indicating that Cx26 
and Cx32 may compensate for each other during later stages of pregnancy and lactation 
[201]. Further studies by Locke at al. showed that Cx26 and Cx32 formed heteromeric 
Cx26-Cx32 connexons in the luminal epithelial cells of the mouse mammary gland [198, 
202]. Locke and his colleagues found that at the onset of parturition, Cx26 was 
predominant in the heteromeric connexon; however, the Cx32 ratio increased throughout 
the lactation and heteromeric connexons were finally shifted into homomeric Cx32 
channels, which have wider pores than homomeric Cx26 channels [202]. Cx30 can form 
heteromeric channels with both Cx26 and Cx32. Compared to Cx26 channels, both Cx32 
homomeric channels and Cx26-Cx30/Cx30-Cx32 heteromeric channels are more 
insensitive to taurine, an amino acid used for osmolytic balance during milk protein 
synthesis, indicating an important role for Cx30 or Cx32 at the lactation stage [203].  
Both the GJIC-dependent and GJIC-independent functions of connexins have 
been found to involve in the regulation of mammary gland development. El-Sabban et al. 
reported that enhanced GJIC induced partial differentiation of mammary epithelial cells, 
in the absence of exogenouly provided basement membrane [204]. The same group also 
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reported that heterocellular interaction between SCg6 cells and SCp2 cells increased the 
association of connexins with α-catenin and ZO-2, leading to the recruitment of β-catenin 
into the gap junctional complex, which prevented translocation of β-catenin to the 
nucleus, stabilized gap junctions, and contributed to the GJ-induced functional 
differentiation of mammary epithelial cell [205].  
Collectively, all these findings indicate that connexins have stage-specific roles in 
the development and differentiation of normal mammary glands.  
 1.2.3.3 Role of Connexin in Breast Cancer 
 
Human breast tumors are diverse in the epidemiological risk factors, the 
development histories, and the responses to therapies. The tumors could be classified into 
subtypes by genetic array testing or immunohistochemistry [206-209]. Based on global 
gene expression analyses, four molecular intrinsic subtypes of breast cancer, including 
Luminal A, Luminal B, HER2-enriched (HER2 is also known as ERBB2), and Basal-like, 
have been identified and intensively studied [206]. These subtypes are different in 
genomic complexity including key genetic alterations and clinical prognosis [210, 211]. 
Although genetic array testing is a powerful tool to recognize the subtype of breast cancer, 
it is not always feasible to obtain gene expression array information. Recently, a 
simplified classification proposed by Cheang et al. has been adopted [212]. The new 
classification is based on clinicopathological criteria, using immunohistochemical 
definition of estrogen receptor (ER) and progesterone receptor (PR), the detection of 
overexpression and/or amplification of the human epidermal growth factor receptor 2 
(HER2) oncogene, and Ki-67 labeling index, a marker of cell proliferation, to identify 
tumor subtypes. Breast cancer subtypes defined by this method are similar to but not 
identical to intrinsic subtypes. Intrinsic breast cancer subtypes and their clinicopathologic 
definitions are listed in Table 3.  
Subtypes of Breast Cancer 
The diversity of the subtypes results in different metastatic behaviors. Follow-up 
studies of patients with early-stage breast cancer showed that the median durations of 
survival with distant metastasis were 2.2 years for Luminal A, 1.6 years for Luminal B, 
1.3 years for Luminal/HER2 (Luminal B/HER2 positive), 0.7 years for HER2-enriched, 
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and 0.5 years for Basal-like [213]. The metastatic sites vary among different subtypes. 
Bone was the most common metastatic site in all subtypes except Basal-like [213]. Both 
HER2-enriched and Basal-like tumors have higher rate of brain and lung metastases, and 
HER2-enriched tumors has high rate of liver metastasis [213].  
Because the factors of breast cancer, including histological grade, invasiveness 
and metastasis, hormone receptor and HER2 status, and proliferation, are determinants 
for the chemotherapy, the diversity of these factors in subtypes makes the response to 
chemotherapy differed by subtype. Recently, it has been widely accepted that Luminal A 
subtype is less responsive to chemotherapy [214]. For Luminal B disease, both 
anthracyclines and taxanes have been considered to be used in the chemotherapy. These 
anti-cancer agents were also recommended to the treatment of HER2 positive disease. 
Moreover, the use of trastuzumab, a specific antibody which targets HER2/neu protein on 
the surface of HER2 positive cells, is a standard adjuvant treatment for patients with 
HER2 positive disease [215]. One year of trastuzumab therapy has been regarded as an 
optimal adjuvant therapy for HER2 positive patients [215]. For Basal-like (triple negative) 
disease, in addition to the anthracyclines and taxanes, an alkylating agent is also used, 
especially for triple negative tumors with BRCA1 mutation [216]. Treatment 
recommendations for all subtypes are listed on Table 3.  
 
Intrinsic 
Subtypes 
Clinicopathologic Definition Type of Therapy 
Luminal A 
Luminal A 
ER and/or PR positive, HER2 negative, Ki-
67 low 
Endocrine therapy 
alone 
Luminal B 
Luminal B (HER2 negative) 
ER and/or PR positive, HER2 negative, Ki-
67 high 
Endocrine ± cytotoxic 
therapy 
Luminal B (HER2 positive) 
ER and/or PR positive, HER2 over-
expressed or amplified, any Ki-67 
Cytotoxics + anti-
HER2 + endocrine 
therapy 
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HER2-enriched 
HER2 positive (non luminal) 
ER and PR absent, HER2 over-expressed or 
amplified 
Cytotoxics + anti-
HER2 
Basal-like 
Triple negative (ductal) 
ER and PR absent, HER2 negative 
Cytotoxics 
Table 3. Intrinsic subtypes of breast cancer, clinicopathologic definitions, and 
relative type of therapy. 
 
Because gap junctions and connexins play stage-specific functions in the 
development and differentiation of normal mammary glands (as discussed above), it is 
not surprising that loss of connexin expression and deficiency of GJIC may contribute to 
breast carcinogenesis. Mammary gland a valuable model for the investigations of gap 
junction and/or connexin functions in every stage of cancer, from onset to progression 
and metastasis.   
Breast Cancer and Connexin 
In breast carcinogenesis, connexins have long been considered as tumor 
suppressor genes, due to the aberrant expression or localization of connexins and the 
deficiency of GJIC in breast cancer cell lines and tissues. However, recent data reported 
that invasive breast carcinomas express high levels of connexins, indicating that 
connexins may play a different role at the late stage of carcinogenesis [188, 217, 218]. 
Until now, it is generally accepted that aberrant connexin expression and impaired GJIC 
promote tumorigenesis at the initial steps of this process [194, 219], whereas, although 
some contradictory results have been reported [220, 221], expression of connexins and 
functional GJIC are found to be crucial, at later stages, for migrating cells to invade, 
interact with endothelial cells, and metastasis [186, 217, 219].  
Several studies using both primary breast cancer cell lines and breast cancer 
patient tissue samples reveal a loss of overall connexin protein expression or a re-
localization of the connexin to intracellular compartments, resulting in a loss of GJIC 
compared to normal mammary cells and breast tissues [139, 150, 222, 223]. For example, 
Cx26 and Cx43 have been reported to be down-regulated in primary cells derived from 
human breast tumors as well as in rat mammary tumors and breast cancer cell lines [139, 
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224]. Over-expression of Cx26 in GJ-deficient human MCF-7 breast cancer cells, which 
maintain the phenotype of early-stage cancers, restored cell-cell communication and 
reduced cell malignant properties, including the proliferation rate, the saturation density, 
and the anchorage-independent growth capacity [225]. Retroviral delivery of Cx26 and 
Cx43 to HBL100 breast cancer cell line that lacks connexin expression resulted in a 
dramatic inhibition of tumor growth in vivo [226]. Interestingly, this inhibition is 
independent of the formation of gap junctions [226]. All these results suggest a tumor-
suppressive role for connexins at the early stage of carcinogenesis.  
Contrary to a tumor-suppressive role for connexins, several studies have reported 
an increased connexin expression in breast cancer tissue. Cx26 and Cx43 expression was 
detected in more than 50% of the invasive breast carcinomas, as compared to normal 
tissue samples, although the location of connexins were cytoplasmic [227]. In addition, 
phosphorylated form of Cx43 was up-regulated in all cells of invasive breast carcinomas 
as well as in myoepithelial cells and transformed luminal cells of in situ carcinomas [228]. 
Furthermore, the levels of cytoplasmic Cx43 and Cx26 expressions have been correlated 
to advanced histological grade of the tumor, larger tumor size and poor prognosis in 
breast cancer patients [217, 229]. These results challenge the notion of connexins as 
tumor suppressors and lead to re-evaluation of connexin functions at the late stage of 
carcinogenesis. At metastatic stage, connexins have been shown to be highly implicated 
at intravasation and extravasation sites. For instance, Cx43 expression increased in tumor 
cell/endothelial cell contact areas in vitro and in vivo, where it marked the sites of 
metastases to the lungs [230]. In addition, GJIC via Cx43 increased the adhesion of breast 
cancer cells to lung endothelial cells. However, the adhesion was decreased in breast 
cancer cells with a dominant-negative Cx43 mutation, which has non-functional GJIC, 
indicating the importance of Cx43 and GJIC in metastasis [230]. Other studies showed 
that expressions of Cx26, Cx32 and Cx43 were up-regulated in lymph nodes metastases 
compared to primary tumors [188, 231]. 70% of Cx26, Cx32 and Cx43-negative primary 
tumors developed Cx26, Cx32, and Cx43-positive lymph node metastases, suggesting an 
increase of connexin expression during breast cancer progression resulting in a more 
malignant phenotype [231].  
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Collectively, all these reports indicate that connexins and gap junctions can 
function as either suppressor or enhancer in breast tumorigenesis, depending on the stage 
of tumor formation. The stage-specific roles of connexins and GJIC suggest that 
restoration of connexin expression and GJIC at primary stages of tumorigenesis might 
have beneficial effects in breast cancer therapy. However, considering the promotion 
function of connexins and GJIC on the late-stage disease, down-regulation of connexin 
and reduction of GJIC should be applied to inhibit the metastasis. 
 1.3 Connexins and Gap Junctions as Therapeutic Targets 
As discussed above, connexins have both GJIC-dependent and GJIC-independent 
functions in the formation and regulation of connexin-related diseases, especially cancer, 
suggesting that they are potential therapeutic targets. Therefore, development of 
molecules and methods that can modulate connexin expression and GJIC has become a 
strategy in cancer treatment.  
 1.3.1 Therapeutic Approaches Related to GJIC 
Although GJIC has paradoxical roles in carcinogenesis, either as a suppressor or 
facilitator, increasing evidence showed that up-regulation of GJIC at primary stages of 
tumorigenesis had beneficial effects in cancer therapy. The main strategy in GJIC-based 
cancer therapies relied on the “bystander effect”, a mechanism by which cytotoxic 
molecules or signals are transferred from target cells to neighboring cells. When there is 
lack of GJIC in cancer cells, the effects of drugs are limited to the target cells, whereas 
bystander effect provides a route for drugs to spread throughout a tumor mass and induce 
more cell death. It is an important factor which is related to drug sensitivity and efficacy. 
Bystander effect has been applied in gene therapy, radiation therapy, immunotherapy and 
chemotherapy. For example, in gene therapy, after enhancing connexin 43 (Cx43) and 
GJIC by 8-bromo-cyclic-AMP treatment, gene therapy effect was strengthened by herpes 
simplex virus thymidine kinase/gancyclovir (HSV-TK/GCV) system [232]. In radiation 
therapy, the bystander effect amplified cells’ responsiveness to radiation therapy through 
the transmission of damage signals (such as superoxide radicals, reactive nitrogen 
species, and other DNA damage molecules) from irradiated cells to non-irradiated cells 
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[233]. In immunotherapy, MCL (melanoma cell lysate)/TNF-stimulated human dendritic 
cells (hDCs) allowed melanoma antigen transfer via bystander effect, which facilitated 
antigen cross-presentation and dendritic-cell-mediated melanoma-specific T cell response 
[234]. The MCL/TNF-stimulated hDCs have been used in melanoma immunotherapy in 
patients and triggered tumor-specific immune responses [235]. In chemotherapy, 
bystander effect has been shown to potentiate the efficacy of anti-cancer drugs not only 
through transduction of the drugs, but also through the transmission of drug-induced 
death signals. A cisplatin-induced death signal involving the Ku70, Ku80 and DNA-
dependent protein kinase complex, has been reported to be transmitted from the target 
cells to neighboring cells through gap junctions [236].  
Several molecules, natural or synthesized, have been reported to up-regulate 
GJIC. The natural molecule resveratrol reversed the GJIC-blocking effects of TPA and 
DDT [237]. (-)-Epicatechin, a flavonoid found in green tea, stimulated GJICand 
counteracted GJIC inhibition by TPA in rat liver epithelial cells [238]. Combination of 
dibutyryl-cyclic AMP (db-cAMP) and all-trans-retinoic acid (tRA) enhanced GJIC and 
increased Cx43 expression [232]. 4-phenylbutyrate (4-PB), a HDAC inhibitor (HDACi) 
increased GJIC in pancreatic cancer cells [239]. In addition, diverse carotenoids have 
been reported to induce GJIC in fibroblast cells [240].  
 1.3.2 Therapeutic Approaches Related to Connexin Expression 
Based on the anti-tumor growth effect of connexins in cancer, especially in 
primary cancer, restoration of connexin expression has been considered as a therapeutic 
approach in cancer treatment. Over-expression of connexins by molecules targeting 
transcriptional and post-transcriptional regulation pathways has been achieved in some 
cancer cell lines.  
On the transcriptional level, inhibitors of HDAC, a group of enzymes involved in 
chromatin remodeling, have been reported to restore Cx43 expressions as well as GJIC. 
For example, The HDAC inhibitor Trichostatin A (TSA) restored Cx43 expression and 
GJIC in prostate cancer cells [241]. Another factor that correlates with connexin gene 
regulation is DNA methylation. The DNA demethylating agent 5-aza-2’-deoxycytidine 
(5-aza-C), was reported to restore Cx32 expression in human renal cell carcinoma (RCC), 
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and subsequently inhibit the xenograft tumor growth [242]. Connexin transcription is also 
regulated by proteins via specific signaling pathways. For instance, the AML1-ETO 
fusion protein was shown to transcriptionally up-regulate Cx43 expression through JNK 
signaling pathway [243]. Furthermore, a protein complex containing HSP90 and c-Myc 
was reported to interact with Cx43 promoter and up-regulate Cx43 through Ras-Raf-
MAPK pathway [34].  
On the post-translational level, studies of connexin restoration focus on the 
phosphorylation and degradation. BQ123, an antagonist of ETA receptor (ETAR), was 
shown to counteract Cx43 phosphorylatin and GJIC inhibition induced by endothelin-1 
(ET-1), a ligand for the ETAR, indicating the role of phosphorylation in connexin 
expression and GJIC function. [244]. Treatment with the proteasome inhibitor MG132 
decreased Cx43 degradation, increased Cx43 expression, and sensitized cells to the pro-
apoptotic effect of MG132, suggesting that inhibition of degradation pathways is an 
alternative strategy to restore connexin expression.  
 1.3.3 PQ1 as a Gap Junction Enhancer 
In search of effective gap junction enhancers, we collaborated with Dr. Duy H. 
Hua in the Department of Chemistry at Kansas State University who synthesized a series 
of quinoline derivatives (named PQs). Computational docking studies showed that PQ1, 
6-methoxy-8-[(3-aminopropyl)amino]-4-methyl-5-(3-
trifluoromethylphenyloxy)quinoline, interacts with the partial crystal structure of 
connexon, indicating the potential role of PQ1 in gap junction [245]. Further biological 
studies showed that PQ1 increased GJIC and had cytotoxicity in human breast cancer 
cells. 200 nM PQ1 significantly increased GJIC in T47D breast cancer cells, but had no 
effect on the GJIC in normal mammary epithelial cells [245]. In addition to the effect on 
GJIC, PQ1 decreased cell viability, inhibited colony growth, and attenuated xenograft 
tumor growth of T47D cells; however, no cytotoxic effects of PQ1 were detected on 
HMECs [245, 246]. Combinational treatment of T47D cells with Tamoxifen and PQ1 
synergistically decreased cancer cell proliferation, viability and colony growth [246]. All 
these reports suggest that PQ1 is a gap junction enhancer as well as a potential anti-
cancer agent. However, there are still many questions which need to be answered before 
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we have a comprehensive understanding of the mechanism and function of PQ1: How 
PQ1 exerts its anti-cancer function? Can PQ1 potentiate the efficacy of anti-cancer drugs 
through bystander effect? Does PQ1 have side effects? What is the mechanism of PQ1 in 
the regulation of gap junction? Further studies are needed to answer these questions.  
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Chapter 2 -  Hypotheses and Objectives 
 2.1 Hypotheses 
1. The anti-cancer effects of PQ1, 6-methoxy-8-[(3-aminopropyl)amino]-4-methyl-5-(3-
trifluoromethylphenyloxy)quinoline, on T47D breast cancer cells have been reported; 
however, the mechanism of the anti-cancer effect is unclear. Many quinoline derivatives have 
been shown to induce apoptosis in cancer cells. PQ1 is a quinoline derivative; therefore, the 
hypothesis is that the anti-cancer effect of PQ1 is mediated via the apoptotic pathways in 
T47D breast cancer cells. 
2. Further studies demonstrated that PQ1 acts as a gap junction enhancer by increasing GJIC in 
T47D cells. Therefore, the second hypothesis is that PQ1 can be used in the combinational 
treatment with anti-cancer drugs to increase the efficacy of anti-cancer drugs through 
bystander effect. 
3. Minimal toxicity of PQ1 on normal human mammary epithelial cells (HMECs) was observed 
within the effective doses of anti-cancer effects and GJIC-mediated responses. Thus, the 
hypothesis is that PQ1 can be administered with low toxicity to normal organs. 
 2.2 Objectives 
1. To determine the mechanism of  PQ1 anti-cancer effect in T47D breast cancer cells 
2. To evaluate the combinational effects of PQ1 and cisplatin 
3. To examine the effects of PQ1 on normal organs 
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Figure 2.1 Schematic presentation of hypotheses and objectives  
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Chapter 3 - PQ1, a Quinoline Derivative, Induces Apoptosis in 
T47D Breast Cancer Cells through Activation of Caspase-8 and 
Caspase-9 
 3.1 Abstract 
Apoptosis, a programmed cell death, is an important control mechanism of cell 
homeostasis. Deficiency in apoptosis is one of the key features of cancer cells, allowing cells to 
escape from death. Activation of apoptotic signaling pathway has been a target of anti-cancer 
drugs in an induction of cytotoxicity. PQ1, 6-methoxy-8-[(3-aminopropyl)amino]-4-methyl-5-
(3-trifluoromethylphenyloxy)quinoline, has been reported to decrease the viability of cancer 
cells and attenuate xenograft tumor growth. However, the mechanism of the anti-cancer effect is 
still unclear. To evaluate whether the cytotoxicity of PQ1 is related to induction of apoptosis, 
the effect of PQ1 on apoptotic pathways was investigated in T47D breast cancer cells. PQ1-
treated cells had an elevation of cleaved caspase-3 compared to controls. Studies of intrinsic 
apoptotic pathway showed that PQ1 can activate the intrinsic checkpoint protein caspase-9, 
enhance the level of pro-apoptotic protein Bax, and release cytochrome c from mitochondria to 
cytosol; however, PQ1 has no effect on the level of anti-apoptotic protein Bcl-2. Further studies 
also demonstrated that PQ1 can activate the key extrinsic player, caspase-8. Pre-treatment of 
T47D cells with caspase-8 or caspase-9 inhibitor suppressed the cell death induced by PQ1, 
while pre-treatment with caspase-3 inhibitor completely counteracted the effect of PQ1 on cell 
viability. This report provides evidence that PQ1 induces cytotoxicity via activation of both 
caspase-8 and caspase-9 in T47D breast cancer cells.  
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 3.2 Introduction 
Quinoline is a heterocyclic aromatic nitrogen compound which is often used for the 
design of many synthetic compounds with diverse medical benefits [1]. Recent studies found that 
numerous quinoline derivatives display potent anti-cancer activity by targeting different cellular 
pathways, including multidrug resistance, proliferation, and apoptosis [2-4]. Apoptosis is a 
programmed cell death, an important control mechanism of normal cell physiology [5, 6]. 
Deficiency in apoptosis is one of the key features of cancer cells [7]. Restoring and activating 
apoptosis in cancer cells is a major target of cancer treatment [8]. By using cell- and caspase-
based high-throughput screening assays, Kemnitzer et al. found a new series of apoptosis 
inducers, the 1-benzoyl-3-cyanopyrrolo[1,2-α]quinolines, among which the compound 1-(4-(1H-
imidazol-1-yl)benzoyl)-3-cyanopyrrolo[1,2-α]quinoline displayed high cytotoxic activity in 
T47D human breast cancer cells, HCT116 human colon cancer cells, and SNU398 hepatocellular 
carcinoma cancer cells [9]. Sharma et al. reported that a quinoline derivative, 8-methoxy 
primido[4’,5’:4,5]thieno(2,3-b)quinolin-4(3H)-one (MPTQ), induces apoptosis in K562 myeloid 
leukemia cell line and inhibits tumor progression in mice bearing different types of tumors [4]. 
These reports indicate that quinoline derivatives are potential anti-cancer drugs, targeting the 
induction of apoptosis.  
Caspases, a class of proteases, play an essential role in the induction and execution of 
apoptosis. Caspase-dependent apoptosis can be generally divided into two signaling pathways: 
the intrinsic pathway and the extrinsic pathway [10]. The intrinsic pathway is initiated from 
within the cell and depends on the balance of the pro- and anti-apoptotic members of Bcl-2 
family proteins. The internal signal, like DNA damage or severe cellular stress, causes pro-
apoptotic protein, Bax, to migrate to the surface of the mitochondrion, where it inhibits the 
protective effect of anti-apoptotic protein Bcl-2. Bax generates holes in the mitochondrial 
membrane, which permits the leakage of cytochrome c to the cytoplasm. Cytochrome c activates 
caspase-9 and subsequently results in the cleavage of caspase-3 as the cell death executioner 
[11]. In contrast, the extrinsic pathway is triggered by a signal outside of the cells. These signals 
are pro-apoptotic ligands that bind to their specific receptors on the plasma membrane and 
activate the checkpoint protein caspase-8 [12]. Caspase-8 signal transduction eventually activates 
the caspase-3 to initiate cell death [12]. Some compounds trigger only one apoptotic pathway, 
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while others can activate both pathways. For example, the MPTQ is reported to trigger two 
signaling pathways by activating both caspase-8 and caspase-9 [4].  
PQ1, 6-methoxy-8-[(3-aminopropyl)amino]-4-methyl-5-(3-trifluoromethylphenyloxy)-
quinoline, has been reported to possess anti-cancer activity in breast cancer cells but not in normal 
human mammary epithelial cells (HMECs) (Fig. 3.1). Previous studies showed that one µM of 
PQ1 decreased cell viability to 50% in T47D breast cancer cells and attenuated 70% of T47D 
xenograft tumor in nude mice [13]. In the present study, we investigated whether the cytotoxicity 
induced by PQ1 is mediated through apoptosis. The results of Western blotting and 
immunofluorescence assays showed that PQ1 activated mitochondrial intrinsic pathways by 
increasing Bax, releasing cytochrome c from the mitochondria to cytosol, and subsequently 
activating caspase-9. Furthermore, PQ1 increased the level of active caspase-8. This report 
demonstrates that PQ1 induces cytotoxicity in T47D cells via both caspase-8 and caspase-9 
mediated apoptotic pathways. 
 
Figure 3.1 Effects of PQ1 on T47D breast cancer cell colony and human mammary 
epithelial cell (HMEC) colony 
Base agar plates were prepared containing 0.8% agar and 0.4% agar in Ham’s F12. HMECs and 
T47D cells (5 x 104 cells/33 mm2 well) were suspended in 100 µl of Ham’s F12 with 0.4% agar 
and plated. These plates were maintained at 37°C for 7 days and examined for the presence of 
colonies. Individual colonies of 50 µm or greater were examined. HMECs and T47D cells were 
65 
 
treated with 1, 10 and 100 nM PQ1 and SA (succinic acid). Individual colonies of 50 µm or 
greater were examined. Statistical significance, *p<0.05, of at least three experiments. (Cited 
from dissertation of Aibin Shi, Kansas State University, http://hdl.handle.net/2097/1638) 
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 3.3 Meterial and Methods 
 3.3.1 Reagents and Antibodies 
PQ1, 6-methoxy-8-[(3-aminopropyl)amino]-4-methyl-5-(3-trifluoromethylphenyloxy)-
quinoline, was obtained as described by Shi at al. [14] and graciously provided by Dr. Duy Hua 
(Kansas State University). Acridine orange/propidium iodide (AO/PI) dye for viability assay was 
purchased from Nexcelom Bioscience (Lawrence, MA, USA). Anti-cleaved caspase-3, anti-
caspase-8 p18 (H-134), anti-caspase-9 p35 (H-170), anti-Bax, and anti-Bcl-2 antibodies were all 
obtained from Santa Cruz Biotechnologies (Santa Cruz, CA, USA). Rabbit anti-cytochrome c, 
HRP-linked anti-rabbit/mouse, anti-cleaved caaspase-8 (Asp391), and anti-cleaved caspase-9 
(Asp315) antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA). 
Mouse anti-cytochrome c and rabbit anti-Cox IV antibodies were obtained from Abcam 
(Cambridge, MA, USA). Alexa-568-conjugated anti-rabbit IgG and Alexa-488-conjugated anti-
mouse IgG antibodies were obtained from Invitrogen (Camarillo, CA, USA). Caspase-3 inhibitor 
(Ac-DMQD-CHO), caspase-8 inhibitor (Ac-IETD-CHO), and caspase-9 inhibitor (Ac-LEHD-
CHO) were purchased from Enzo Life Sciences (Enzo Life Sciences, Farmingdale, NY, USA).  
 3.3.2 Cell Line and Cell Culture 
T47D human breast cancer cell line was purchased from American Type Cell Culture 
(ATCC) (Manassas, MA, USA). Cells were grown in RPMI-1640 (Sigma-Aldrich, St Louis, 
MO, USA) supplemented with 10% fetal bovine serum (Atlanta Biological, Lawrenceville, GA, 
USA), 1 mM sodium pyruvate, 10 mM hepes, 4.5 g/L glucose, 2 g/L sodium bicarbonate, and 
0.2 units/ml bovine insulin. Cells were maintained in T-75 flasks at 37 °C with 5% CO2 and 
cultured in 6-well plates or T-25 flasks for experimental analysis.  
 3.3.3 Cell Morphology 
T47D cells were cultured in T-25 flasks until 80% confluent state. Cells were treated with 
DMSO and 100, 200, and 500 nM PQ1 for 24 and 48 hours. Cells without any treatment were 
used as controls. Cell morphology was captured using Nikon 80i light microscope.  
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 3.3.4 Cell Viability Assay 
Cell viability was measured using Acridine Orange/Propidium Iodide (AO/PI) staining 
method. T47D cells were cultured into 6-well plates until 80% confluent state. Cells were treated 
with DMSO and 100, 200, and 500 nM PQ1 for 24 and 48 hours. Cells without treatment were 
used as controls. Detached and trypsinized cells were combined to access the total cell viability 
after treatment. Samples were centrifuged at 2,000 rpm using a HERMLE Z300K centrifuge with 
rotor 221.05 V01 (Labnet, Woodbridge, NJ, USA) for 5 minutes. Media and trypsin supernatant 
were discarded and cell pellet was resuspended in 1 X phosphate-buffered saline (PBS). A cell 
suspension was mixed with AO/PI dye (5 µg/mL AO and 100 µg/mL PI in PBS) at 1:1 ratio. 
Viable and dead cells were visually examined by the Cellometer Auto 2000 (Nexcelom 
Bioscience, Lawrence, MA, USA). AO is a nuclear stain that is used to stain live cells and emits 
in the “green” range. PI is a fluorescent stain that only penetrates dead cells and emits in the 
“red” range. After taking both “green” and “red” fluorescent images, all fluorescent cells in each 
channel were counted and the concentration of live (green) and dead (red) cells as well as 
viability were determined. 
 3.3.5 Flow Cytometry 
Apoptotic cells were analyzed by flow cytometry using the Alexa Fluor 488 Annexin 
V/Dead Cell Apoptosis Kit (Invitrogen, Camarillo, CA, USA). T47D cells were treated with 
DMSO and various concentrations of PQ1 for 24 and 48 hours. Cells were harvested and washed 
with cold PBS. After centrifugation, supernatant was discarded and cell pellets were resuspended 
in 1 X annexin-binding buffer to the final concentration at 1 x 106 cells/ml. After adding 1 µL of 
Alexa Fluor 488 annexin V and 1 µL of 100 µg/ml PI working solution into each 100 µL cell 
suspension, cells were incubated at room temperature for 15 minutes. 400 µL of 1 X annexin-
binding buffer were added into the cell suspension after incubation. Stained cells were detected 
by flow cytometry measuring the fluorescence emission at 530 nm and 575 nm. 
 3.3.6 Mitochondria Isolation 
Mitochondria were isolated by using Mitochondria Isolation Kit from Thermo Scientific 
(Rockford, IL, USA). Followed the manufacturer’s instructions, control and treated cells were 
trypsinized and centrifuged at 850 x g using an Eppendorf centrifuge 5415R with rotor F-45-24-
11 for 2 minutes. Cell pellets were treated with mitochondria isolation reagents. Cytosol and 
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mitochondria fractions were isolated by two consecutive centrifugation steps (700 x g and 12,000 
x g, respectively) at 4 °C. After isolation, expressions of cytochrome c in mitochondria and 
cytosol were examined by western blot analysis. 
 3.3.7 Western Blot Analysis 
T47D cells were cultured in T-25 flasks until 80% confluent state and then treated with 
DMSO and PQ1 as indicated for 48 hours. Cells without treatment were used as controls. Cells 
were washed with PBS for three times and harvested in lysis buffer (Cell Signaling Technology, 
Danver, MA, USA). Cell lysates were sonicated using Vibra-Cell sonicator (Sonics & Materials 
Inc, Danbury, CT, USA) and then centrifuged at 13,000 rpm using an Eppendorf centrifuge 
5415R with rotor F-45-24-11 for 30 minutes at 4 °C. Supernatants were collected and measured 
for its total protein concentration. Thirty µg of samples were separated by 4-20% gradient SDS-
PAGE for 35 minutes at 200 Volts, and transferred to nitrocellulose membranes (Midwest 
Scientific, Saint Louis, MO, USA). After blocked with 5% milk for 30 minutes, membranes were 
immunoblotted against protein of interest. Immunoreactions using chemiluminescence were 
visualized by FluoChem E Imaging Instrument (ProteinSimple, Santa Clara, CA, USA). 
Intensities of the bands were digitized using Un-Scan-It software (Silk Scientific Inc., Orem, 
Utah, USA).  
 3.3.8 Immunofluorescence and Confocal Microscopy 
T47D cells cultured on coverslips in 6-well plates were treated with DMSO and PQ1 for 
48 hours.  Cells were rinsed by warm PBS and fixed with 2% paraformaldehyde for 20 minutes 
at room temperature. Fixed cells were washed 3 times with PBS and then permeabilized with 
0.1% Triton X-100 for 8 minutes. Cells were washed 3 times with PBS again, and blocked with 
2.5% BSA in PBS for 1 hour at room temperature. After blocking, cells were incubated with 
primary antibodies overnight at 4°C and Alexa-conjugated secondary antibodies for 1 hour at 
room temperature. DAPI was used for nuclei stain. The slides were mounted with prolong-
antifade reagent (Invitrogen, Camarillo, CA, USA), sealed and observed under a confocal 
microscope (Carl Zeiss LSM 700 META, Narashige, MN, USA).  
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 3.3.9 Caspase Inhibitor Assay 
T47D cells were cultured into 6-well plates until 80% confluent state. Cells were 
pretreated with caspase-3 inhibitor (Ac-DMQD-CHO), caspase-8 inhibitor (Ac-IETD-CHO), or 
caspase-9 inhibitor (Ac-LEHD-CHO) at concentration of 20 µM for 1 hour, and then treated with 
500 nM PQ1 for 23 hours. Cells without any treatments or treated with 500 nM PQ1 for 24 hours 
were used as controls. After treatment, cell viability was assessed by trypan blue method. Cells 
floated in the media were collected and cells attached to the wells were trypsinized. Two parts of 
cells were combined together, centrifuged and resuspended. A cell suspension was mixed with 
trypan blue dye (0.2% in PBS) at 1:1 ratio and viable cells were examined by the Cellometer 
Auto 2000 (Nexcelom Bioscience, Lawrence, MA, USA). 
 3.3.10 Statistical Analysis 
Statistical analysis of data was performed using student’s t-test Data presented were 
expressed as mean ± standard deviation (S.D.) of at least three independent experiments. 
Significance was considered at p-value < 0.05.  
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 3.4 Results 
 3.4.1 PQ1 Changes Cell Morphology and Induces Cell Death in T47D Breast Cancer 
Cells 
Cytotoxicity of PQ1 on T47D breast cancer cells was determined by observed 
morphological change and dual-fluorescence viability assay. T47D breast cancer cells were 
treated with DMSO and 100, 200, and 500 nM of PQ1 for 24 and 48 hours. Cells without 
treatment were used as controls. Differences in cell morphology were observed between PQ1-
treated and control cells under 20X magnification of light microscopy. Morphological changes 
including cell rounding, shrinkage, and detachment were found in PQ1-treated cells in a dose-
dependent manner (Fig. 3.2). Compared with cells treated with PQ1 for 24 hours, cells treated 
with the same concentration of PQ1 for 48 hours had more significant morphological changes 
(Fig.3.2). These results suggested that PQ1 induces morphological changes in a dose- and time-
dependent manner. To determine if the changes of morphology were associated with cell death, 
cell viability was examined using dual-fluorescence (AO/PI) viability assay. The results showed 
that PQ1 decreased cell viability in a dose- and time-dependent manner as well. 100 nM PQ1 did 
not significantly reduce cell viability with 24-hour of treatment, but significantly reduced cell 
viability to 85% with 48-hour of treatment (Fig. 3.3). 500 nM PQ1 showed a 37% and 47% 
reduction of cell viability at 24- and 48-hour of treatment, respectively (Fig. 3.3). DMSO, a PQ1 
solvent, showed no changes on cell morphology and viability at any time points (Fig. 3.2, 3.3). 
All these results indicate that PQ1 induces morphological changes and decreases cell viability in 
T47D breast cancer cells. 
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Figure 3.2 Effect of PQ1 on cell morphology in T47D breast cancer cells  
T47D cells were treated with DMSO and various concentrations of PQ1 for 24 and 48 hours. 
Cells without treatments were used as controls. Cell morphology was captured using the light 
microscope under 20X magnification. The scale bar represents a 100 µm in size. 
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Figure 3.3 Effect of PQ1 on cell viability in T47D breast cancer cells  
T47D cells were treated with DMSO and various concentrations of PQ1 for 24 and 48 hours. 
Cells without treatments were used as controls. Cell viability was determined by the AO/PI 
staining method. Data were obtained in three independent experiments and are represented as the 
mean ± S.D. * P-value is <0.05 compared to control. **P-value is <0.05 compared to 24 hours 
treatment. 
 3.4.2 PQ1 Induces Apoptosis in T47D Breast Cancer Cells 
Morphological features of apoptosis including cell shrinkage and detachment were 
observed in Figure 3.2.  Here, the effects of PQ1 on apoptosis were further determined by flow 
cytometry. T47D cells were treated with various concentrations of PQ1 for 24 and 48 hours, and 
cell death was characterized using flow cytometry with propidium iodide (PI) and Alexa Fluor 
488 annexin V staining. The Annexin V-FITC positive /PI negative cells located in the lower 
right quadrant of the histogram represent early apoptotic cells, and the Annexin V-FITC 
positive/PI positive cells in the upper right quadrant represent late apoptotic cells. Figure 3 
shows that 24-hour treatment of 500 nM PQ1 increased the early apoptotic cell population from 
0.44% to 9.25% and the late apoptotic cell population from 0.27% to 12.69%, compared with the 
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control. Same concentration of PQ1 resulted in a higher increase in the percentage of early 
apoptotic cells (from 0.69% to 11.68%) and late apoptotic cells (from 0.57% to 20.23%) at 48-
hour treatment (Fig. 3.4). The results of flow cytometry suggest that PQ1 induces cell death 
through apoptotic pathways in T47D cells.  
 
Figure 3.4 Effect of PQ1 on apoptosis in T47D breast cancer cells  
T47D cells were treated with DMSO and various concentrations of PQ1 for 24 and 48 hours. 
Cells without treatments were used as controls. Apoptotic cells were determined by flow 
cytometry using an Alexa Fluor 488 Annexin V/Dead Cell Apoptosis Kit. Percentages of 
apoptotic cells were showed in quadrants of the histogram. The results represent one of three 
independent experiments. 
 3.4.3 PQ1 Activates Caspase-3 in T47D Breast Cancer Cells 
Caspase-3 is an important executioner at the convergence of multiple caspase-dependent 
apoptotic pathways [15]. Activation of caspase-3 is considered to be the last step of caspase-
dependent apoptosis [16, 17]. To evaluate if PQ1 induces caspase-3 activation of apoptotic 
pathways, expression of active caspase-3 was examined by confocal immunofluorescence 
microscopy. No detectable staining of cleaved caspase-3 was found in cells without treatment or 
cells treated with DMSO (Fig. 3.5). Relative to control, a significant increase of cleaved caspase-
3 staining was detected in the treated cells with 200 and 500 nM PQ1 for 48 hours, indicating 
that 200 and 500 nM PQ1 is sufficient to activate caspase-3 (Fig. 3.5). 
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Figure 3.5 Effect of PQ1 on caspase-3 activation in T47D breast cancer cells  
T47D cells were treated with DMSO and various concentrations of PQ1 for 48 hours. Cells 
without treatments were used as controls. Expression of cleaved caspase-3 was determined by 
confocal microscopic analysis using immunofluorescence staining. Red indicates cleaved 
caspase-3 and blue indicates nuclei stained by DAPI. 
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 3.4.4 PQ1 Activates Caspase-9 Related Intrinsic Apoptotic Pathway in T47D Breast 
Cancer Cells 
The intrinsic mitochondrial apoptotic pathway is characterized by mitochondrial 
membrane permeabilization, cytochrome c release, and caspase-9 activation [17]. The anti-
apoptotic protein Bcl-2 and pro-apoptotic protein Bax are two important members of the Bcl-2 
family involved in the mitochondrial apoptotic pathway. It has been reported that the ratio of 
Bcl-2 to Bax is crucial to the mitochondrial membrane permeabilization and cytochrome c 
release [18]. Here, expression levels of Bcl-2, Bax, cytochrome c, and active caspase-9 were 
studied using both Western blot analysis and confocal microscopy to examine the effect of PQ1 
on the activation of intrinsic apoptotic pathway. Western blot results showed a gradual increase 
in Bax protein with an increase of PQ1; interestingly, there was no change in Bcl-2 level (Fig. 
3.6a, 3.6b). In contrast to control, 200 and 500 nM of PQ1 significantly increased the level of 
Bax to 156% and 176%, respectively (Fig. 3.6b). The results were further confirmed by confocal 
images. PQ1 increased the Bax staining in a dose-dependent manner as well, but again there was 
no change in Bcl-2 staining (Fig. 3.6d). The effects of PQ1 on the levels of Bax and Bcl-2 
subsequently resulted in a decrease of Bcl-2-to-Bax protein ratio. 48-hour treatment with 200 and 
500 nM PQ1 decreased the ratio of Bcl-2 to Bax by 33% and 40%, respectively (Fig. 3.6c). 
These results suggested that PQ1 caused a significant increase of Bax with no change in Bcl-2 
expression, leading to a decrease of the Bcl-2/Bax ratio. 
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Figure 3.6 Effect of PQ1 on the levels of Bax and Bcl-2 in T47D breast cancer cells 
 T47D cells were treated with DMSO and various concentrations of PQ1 for 48 hours. Cells 
without treatments were used as controls. (a) Levels of Bax and Bcl-2 were examined by 
Western blot analysis. Actin was used as a loading control. (b) Graphical presentation of three 
independent experiments shows the pixel intensities of Bax and Bcl-2 normalized to the controls. 
* P-value is <0.05 compared to control. (c) Graphical presentation shows the ratio of Bcl-2 to 
Bax. Data were obtained in three independent experiments and are represented as the mean ± 
S.D. * P-value is <0.05 compared to control. (d) Immunofluorescence was performed to examine 
77 
 
expression levels of Bax and Bcl-2. Red indicates Bax or Bcl-2 as indicated and blue indicates 
the nuclei. 
 
To investigate the cytochrome c release, mitochondrial and cytosolic fractions for 
cytochrome c were isolated after treatment with PQ1 for 48 hours. Western blot analysis showed 
a decrease of cytochrome c in the mitochondria fraction and an increase of cytochrome c in the 
cytosol of the PQ1-treated cells, indicating that PQ1 can trigger the release of cytochrome c from 
the mitochondria into cytosol (Fig. 3.7a). Cytochrome c release was also visualized by confocal 
immunofluorescence microscopy with double-staining of cytochrome c and mitochondrial 
marker. In the untreated and DMSO-treated cells, a significant colocalization of cytochrome c 
and mitochondria was observed (Fig. 3.6b). However, the colocalization signal decreased when 
cells were treated with 500 nM PQ1 (Fig. 3.7b). The reduction of cytochrome c in the 
mitochondria is consistent with the translocation of cytochrome c from the mitochondria to the 
cytosol.  
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Figure 3.7 Effect of PQ1 on the release of cytochrome c from mitochondira to cytosol in 
T47D breast cancer cells 
T47D cells were treated with DMSO and various concentrations of PQ1 for 48 hours. Cells 
without treatments were used as controls. (a) Mitochondria and cytosol were separated by using 
mitochondria isolation protocol as described in Materials and Methods. Western blot analysis of 
cytochrome c was performed. GAPDH and Cox IV were used as loading control in the cytosolic 
and mitochondrial fractions, respectively. Cox IV in the cytosol and GAPDH in the mitochondria 
were used as negative controls. Pixel intensities of protein bands were normalized to pixel 
intensities of loading controls. The results represent one of three independent experiments. 
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Numbers above the blot show fold changes in expression of cytochrome c normalized to control. 
(b) Colocalization of cytochrome c and mitochondria was determined by confocal microscopy. 
Red indicates cytochrome c, green indicates the mitochondrial marker Cox IV, and blue indicates 
nuclei stained by DAPI. Colocalization of cytochrome c and mitochondria is shown in yellow 
color as indicated by arrows. 
 
Released cytochrome c is a critical activator of caspase-9 in intrinsic apoptotic pathway. 
When caspase-9 is activated, the procaspase-9 (approximately 45 kDa) is cleaved into a fragment 
of caspase-9 p35 (approximately 35 kDa) [19, 20]. Therefore, expression level of caspase-9 p35, 
the active form of caspase-9, was examined by both Western blot analysis and confocal 
microscopy using anti-caspase-9 p35 antibodies. Immunoblotting results showed that PQ1 can 
cause a decrease of procaspase-9 and an increase of caspase-9 p35 (Fig. 3.8a, 3.8b). Compared 
with the control, the level of caspase-9 p35 was increased by 34% in cells treated with 500 nM 
PQ1 for 48 hours (Fig. 3.8b). The ratio of active caspase-9 to pro-caspase-9 was increased to 
250% after treated with 500 nM PQ1 for 48 hours (Fig. 3.8c). Confocal images further supported 
that the increase of active caspase-9 was due to the presence of PQ1 (Fig. 3.8d). All the results 
indicate that PQ1 can activate intrinsic apoptotic pathway in T47D cells.  
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Figure 3.8 Effect of PQ1 on the activation of caspase-9 in T47D breast cancer cells  
T47D cells were treated with DMSO and various concentrations of PQ1 for 48 hours. (a) Levels 
of procaspase-9 and caspase-9 p35 were examined by Western blot analysis using anti-caspase-9 
p35 (H-170) antibody which detects the p35 subunit and precursor of caspase-9. Actin was used 
as a loading control. (b) Graphical presentation of three independent experiments shows the pixel 
intensities of caspase-9 p35 normalized to the controls. * P-value is <0.05 compared to control. 
(c) Graphical presentation of three independent experiments shows the ratio of active caspase-9 
(caspase-9 p35) to pro-caspase-9. Results are normalized to the control. * P-value is <0.05 
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compared to control. (d) Immunofluorescence was performed using anti-cleaved caspase-9 
(Asp315) antibody, a rabbit polyclonal antibody specific to the 35 kDa large fragment of 
caspase-9 following cleavage at aspartic acid 315. Red indicates caspase-9 p35 and blue 
indicates the nuclei. Percentages of cells with positive staining were labeled on top of relative 
images. 
 3.4.5 PQ1 Activates Caspase-8 in T47D Breast Cancer Cells 
Caspase-8 is a key reporter of extrinsic apoptotic pathway. When extrinsic pathway is 
initiated, procaspase-8 will be activated and cleaved into active form, leading to the activation of 
caspase-3 [21]. Thus, the activation of capase-8 was examined by comparing the cleaved 
caspase-8 in the presence and absence of PQ1. The results showed that 200 and 500 nM PQ1 can 
significantly cause a cleavage of  procaspase-8 (55 kDa) into 43 kDa, 41 kDa, and 18 kDa 
fragments (Fig. 3.9a). Quantification analysis of caspase-8 p18 showed that 48-hour treatment 
with 500 nM PQ1 increased the level of caspase-8 p18 to 152% relative to control (Fig. 3.9b). 
The results of immunofluorescent staining confirm that 200 and 500 nM PQ1 can cause an 
increase of active caspase-8 (Fig. 3.9c). Overall, the effect of PQ1 mediates not only the 
activation of caspase-9 but also the activation of caspase-8.  
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Figure 3.9 Effect of PQ1 on the activation of caspase-8 in T47D breast cancer cells 
T47D cells were treated with DMSO and various concentrations of PQ1 for 48 hours. (a) Levels 
of procaspase-8 and cleaved caspase-8 (caspase-8 p43, p41 and p18) were examined by Western 
blot analysis using anti-caspase-8 p18 (H-134) antibody, a rabbit polyclonal antibody which 
detects cleaved subunits and precursor of caspase-8. Actin was used as a loading control. (b) 
Graphical presentation of three independent experiments shows the pixel intensities of caspase-8 
p18 normalized to the controls. * P-value is <0.05 compared to the control. (c) 
Immunofluorescence was performed using anti-cleaved caaspase-8 (Asp391) antibody, a rabbit 
monoclonal antibody which detects p18 subunit after cleavage at Asp391 of human caspase-8. 
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Red indicates caspase-8 p18 and blue indicates the nuclei. Percentages of cells with positive 
staining were labeled on top of relative images. 
 3.4.6 Cytotoxicity of PQ1 is Counteracted by Caspase Inhibitors 
To examine if activation of caspases is necessary for PQ1 cytotoxicity, T47D cells were 
pre-treated with 20 µM inhibitor of caspase-3/-8/-9 for 1 hour, and then treated with 500 nM 
PQ1 for 23 hours. Cell viability results showed that the cytotoxicity of PQ1 was completely 
inhibited by the pre-treatment of Ac-DMQD-CHO, a caspase-3 inhibitor (Fig. 3.10). The pre-
treatment of Ac-IETD-CHO, a caspase-8 inhibitor, and Ac-LEHD-CHO, a caspase-9 inhibitor, 
partially inhibited the cytotoxicity of PQ1 (Fig. 3.10). Compared with 500nM PQ1 treatment, 
pre-treatment of Ac-IETD-CHO and Ac-LEHD-CHO increased the cell viability from 64% to 
87% and 84%, respectively. The effects of caspase inhibitors indicate that the cytotoxicity of 
PQ1 is related to the activation of caspase cascade.  
 
Figure 3.10 Effects of caspase inhibitors on the cytotoxicity of PQ1 
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T47D cells were pre-treated with 20 µM caspase-3 inhibitor (Ac-DMQD-CHO), caspase-8 
inhibitor (Ac-IETD-CHO), or caspase-9 inhibitor (Ac-LEHD-CHO) for 1 hour, and exposed to 
500 nM PQ1 for 23 hours. Cells without treatments and cells treated with 500 nM PQ1 for 24 
hours were used as controls. Cell viability was determined by trypan blue method. Data were 
obtained in three independent experiments and are represented as the mean ± S.D. * P-value is 
<0.05 compared to control. **P-value is <0.05 compared to treatment with 500 nM PQ1 for 24 
hours. 
85 
 
 3.5 Discussion 
Cancer is a complex disease with multiple deregulated signaling pathways, including 
apoptosis. Targeting apoptotic pathways has emerged as an attractive approach for cancer 
treatment. So far, numerous quinoline derivatives, both in natural and synthetic products, have 
been reported to possess anticancer activities through induction of different pathways of 
apoptosis [1]. By investigating the effect of quinoline anti-malarials on MCF-7 breast cancer 
cells, Zhou et al. reported that quinidine, a natural alkaloid, and chloroquine, a synthetic alkaloid, 
trigger apoptosis via a p53-dependent pathway [22]. Studies of another quinoline derivative, 
QBS (2-amino-N-quinoline-8-yl-benzenesulfonamide), revealed that QBS induces apoptosis in 
Jurkat cells via a caspase-dependent pathway [23]. The quinoline ring by itself showed no 
evidence of apoptosis induction [22], indicating that this activity is conferred by addition of the 
side chain substituents. The properties of side chains and the steric structures of the derivatives 
may be related to apoptotic pathways selection. In this report, effect of PQ1, 6-methoxy-8-[(3-
aminopropyl)amino]-4-methyl-5-(3-trifluoromethylphenyloxy)quinoline, on apoptosis was 
examined in T47D breast cancer cells. The results showed that PQ1 induces apoptosis by 
initiating caspase cascade. It is not clear that which specific substituent of PQ1 is responsible for 
the activation of apoptosis. More studies are needed to establish the relationship between 
structure and function. 
The present study demonstrated that 200 and 500 nM PQ1 for 48 hours significantly 
increased the population of apoptotic cells (Fig. 3.4) and activated caspase-3, -9 and -8 (Fig. 3.5, 
3.8 and 3.9), indicating that the  effective concentrations of PQ1 in apoptosis induction fall in the 
nM range. 
Caspases are a group of ICE (interleukin 1 β-converting enzyme)-like proteases that play 
a crucial role in apoptosis mediation [24]. Currently, 14 caspases have been identified in humans 
[25, 26], and among them caspase-3 is frequently activated and serves as the executioner. 
Activation of caspase-3 by cleavage of procaspase-3 is considered to be a hallmark of apoptosis 
[27]. By examining the expression of cleaved caspase-3 after PQ1 treatment, we provide 
evidence that PQ1 can induce the activation of caspase-3. Caspase-3 is activated both by 
extrinsic and intrinsic pathways via interacting with two initiator caspases, caspase-8 and 
caspase-9 [28]. In intrinsic pathway, activation of caspase-9 is regulated by cytochrome c and 
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two members of Bcl-2 family, Bax and Bcl-2. The pro-apoptotic factor Bax has been reported to 
form heterodimers with the anti-apoptotic factor Bcl-2, which consequently induce cytochrome c 
release and accelerate apoptosis [29]. Overexpressed Bax counteracts the activity of Bcl-2 [29]. 
However, this view has been questioned due to the fact that the dimeric interaction of Bax and 
Bcl-2 can only be detected in the presence of nonionic detergents, such as Triton X-100 and 
Nonidet P-40 [30]. Furthermore, Knudson and Korsmeyer reported that although there is an in 
vivo competition between Bax and Bcl-2, they are able to regulate apoptosis independently [31]. 
Consistent with this report, our results showed that PQ1 can cause an increase in Bax without 
any changes in Bcl-2, indicating that PQ1 can activate intrinsic apoptotic pathway through Bax-
dependent but Bcl-2 independent mechanisms. Activation of caspase-8 is a crucial step in 
extrinsic apoptotic pathway. 200 and 500 nM PQ1 can cause a cleavage of procaspase-8 into 
active caspase-8 fragments, suggesting that PQ1 can also mediate the activation of extrinsic 
pathway reporter. However, the cleaved caspase-8 can activate caspase-3 through two alternative 
signaling pathways [32, 33]. One pathway is through the activation of caspase-3 directly. 
Another pathway is through the cleavage of BID, a Bcl-2 interacting protein, and the truncation 
of BID (tBID) to translocate to the mitochondria where tBID induces mitochondrial damage and 
releases cytochrome c. The released cytochrome c activates caspase-9 and sequentially activates 
caspase-3. It is not clear which downstream pathway is dominant in caspase-8 mediated 
apoptotic pathway. Further studies are needed to elucidate the downstream events after caspase-8 
activation.  
In conclusion, this study showed that the quinoline derivative, PQ1, exerts its anti-cancer 
effects in T47D breast cancer cells through the induction of both caspase-8 and caspase-9 
mediated pathways of apoptosis. PQ1 can significantly increase bax, cause the release of 
cytochrome c, activate caspase-9 and caspase-8, and subsequently induce caspase-3-mediated 
apoptosis.  
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Chapter 4 - Gap Junction Enhancer Potentiates Cytotoxicity of 
Cisplatin in Breast Cancer Cells 
 4.1 Abstract 
Cisplatin is one of the most widely used anti-cancer drugs due to its ability to damage 
DNA and induce apoptosis. However, increasing reports of side effects and drug resistance 
indicate the limitation of cisplatin in cancer therapeutics. Recent studies showed that inhibition 
of gap junctions diminishes the cytotoxic effect and contributes to drug resistance. Therefore, 
identification of molecules that counteract gap junctional inhibition without decreasing the anti-
cancer effect of cisplatin could be used in combinational treatment, potentiating cisplatin 
efficacy and preventing resistance. This study investigates the effects of combinational treatment 
of cisplatin and PQ1, a gap junction enhancer, in T47D breast cancer cells. Our results showed 
that combinational treatment of PQ1 and cisplatin increased gap junctional intercellular 
communication (GJIC) as well as expressions of connexins (Cx26, Cx32 and Cx43), and 
subsequently decreased cell viability. Ki67, a proliferation marker, was decreased by 75% with 
combinational treatment. Expressions of pro-apoptotic factors (cleaved caspase-3/-8/-9 and bax) 
were increased by the combinational treatment with PQ1 and cisplatin; whereas, the pro-survival 
factor, bcl-2, was decreased by the combinational treatment. Our study demonstrates for the first 
time that the combinational treatment with gap junction enhancers can counteract cisplatin 
induced inhibition of gap junctional intercellular communication and reduction of connexin 
expression, thereby increasing the efficacy of cisplatin in cancer cells.  
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4.2 Introduction 
Cisplatin is a potent agent used in cancer chemotherapy. Since the anti-cancer properties 
of cisplatin were discovered in 1960s, it has been widely employed for treating various cancers, 
including testicular, ovarian, bladder, cervical, head and neck, esophageal, lung and breast cancer 
[1-4]. Numerous studies have provided information to elucidate the molecular mechanism of 
cisplatin cytotoxicity. It is widely accepted that the anti-tumor action of cisplatin is attributed to 
the formation of cisplatin-DNA adducts, inducing several signal pathways and subsequently 
leading to cell cycle arrest, necrosis or/and apoptosis [5]. Recently, other mechanisms without 
DNA-damaging effect have added to the complexity of cisplatin, including the binding of 
cisplatin to cellular proteins and other constituents [6]. Although cisplatin is widely used in 
practice due to its success in the treatment of malignancies; unfortunately, increasing drug 
resistance and side effects of cisplatin evoke a lot of concerns about the application [7].  
Gap junctions (GJ) are intercellular channels connecting adjacent cells to allow small 
molecules of less than 1.2 kDa in size to transport between cells, thereby keeping homeostasis of 
cells and tissues [8, 9]. Many molecular processes including proliferation, differentiation, 
migration and apoptosis, are reported to be affected by this communication [10, 11]. Loss of gap 
junctional intercellular communication (GJIC) and connexins, the gap junction proteins, is a 
hallmark of malignancy [12]. Connexins have been viewed as therapeutic targets in cancer 
treatment due to two important mechanisms: the GJIC-independent mechanism and GJIC-
dependent mechanism [13]. By interacting and regulating tumor-suppressing molecules and 
tumor susceptible genes, connexins exhibit their tumor suppressive functions in a GJIC-
independent manner [14]. A growing amount of reports suggest that over-expressing connexins 
can reduce cancer proliferation and attenuate tumor growth [15]. In addition to this GJIC-
independent mechanism, GJ-based therapies mainly rely on the GJIC-dependent bystander 
effect, a mechanism by which cytotoxic molecules are transferred from target cells to 
neighboring cells [16]. Restoration and/or activation of GJIC have been applied in gene therapy, 
radiation therapy and chemotherapy [17-19]. In chemotherapy, up-regulation of GJIC and 
overexpression of connexins have been used to potentiate drug efficacy and reduce drug 
resistance [20].  
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Cisplatin-induced cytotoxicity has been reported to be transduced to neighboring cells 
through gap junctions. Jensen and Glazer found that the DNA-PK-mediated cytotoxic signal 
triggered by cisplatin was transmitted between cells via gap junctions [21]. The ability of 
activated oncogene, src, to induce cisplatin resistance by producing tyrosine phosphorylation of 
connexin 43 (Cx43) and decreasing GJIC, can be transmitted to adjacent cells by GJIC, even 
when these cells lack src activity. Moreover, this cisplatin resistant effect on neighboring cells 
can be counteracted by overexpression of Cx43 [22]. The analgesics, tramadol and flurbiprofen, 
used in combinational treatment with cisplatin, were shown to depress the cytotoxicity of 
cisplatin via the inhibition effects on gap junctions [23]. Furthermore, cisplatin was reported to 
inhibit GJIC by directly inhibiting the channel activity and decreasing expression of connexins 
[24]. This evidence indicates that inhibition of GJIC and reduction of connexins would decrease 
cytotoxicity of cisplatin and result in cisplatin resistance. Therefore, development of novel agents 
or methods to enhance or restore GJIC in combinational treatment with cisplatin is a new 
strategy to potentiate cisplatin effect and decrease drug resistance.  
PQ1, a derivative of quinoline, was reported as a gap junction enhancer [25]. Gakhar et 
al. reported that 200 nM of PQ1 showed a significant increase in the GJIC in T47D breast cancer 
cells [25]. Combinational treatment of PQ1 and tamoxifen indicated that PQ1 potentiated the 
effect of tamoxifen in T47D cells, indicating the synergistic effect of PQ1 in combinational 
treatment in breast cancers [26].  
In this report, the effects of PQ1 on the cytotoxicity of cisplatin in breast cancer cells 
were examined. Our results showed that PQ1 counteracted the inhibition of GJIC and reduction 
of connexins caused by cisplatin, subsequently enhancing the cytotoxic effect of cisplatin. 
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 4.3 Materials and Methods 
 4.3.1 Reagents and Antibodies 
PQ1, a quinoline derivative, was obtained as described by Shi at al. [27] and graciously 
provided by Dr. Duy Hua (Kansas State University). Cis-Diamminedichloro-platinum, trypan 
blue, Lucifer yellow dye and Rhodamine-dextran dye were all purchased from Sigma (St Louis, 
MO, USA). Anti-Cx43, Alexa-568-conjugated anti-rabbit IgG, and Alexa-594-conjugated anti-
mouse IgG antibodies were obtained from Invitrogen (Camarillo, CA, USA). Anti-Cx32, anti-
Cx26, anti-Ki67, anti-cleaved caspase-3, anti-caspase-8 p18, anti-caspase-9 p35, anti-Bax, and 
anti-Bcl2 antibodies were all purchased from Santa Cruz Biotechnologies (Santa Cruz, CA, 
USA). The HRP-linked anti-rabbit/mouse antibodies were purchased from Cell Signaling 
Technology (Danvers, MA, USA).  
 4.3.2 Cell Line and Cell Culture 
The T47D human breast cancer cell line was purchased from American Type Cell 
Culture (ATCC) (Manassas, MA, USA). The cells were grown in RPMI-1640 (Sigma-Aldrich, 
St Louis, MO, USA) supplemented with 2 g/L sodium bicarbonate, 1 mM sodium pyruvate, 10 
mM hepes, 4.5 g/L glucose, 0.2 units/ml bovine insulin, and 10% fetal bovine serum (Atlanta 
biological, Lawrenceville, GA, USA). Cells were maintained in T-75 cm2 flasks at 37 °C with 
5% CO2 and cultured in 6-well plates or T-25 cm2 flasks for experimental analysis.  
 4.3.3 Cell Morphology 
T47D cells were cultured in six-well plates until 80% confluent state and treated 
according to the following conditions: untreated, PQ1 (100, 200, and 500 nM) alone for 28 
hours, cisplatin (40 µM) alone for 24 hours, and PQ1 (100, 200, and 500 nM) for 4 hours 
followed by addition of cisplatin for 24 hours. Cell morphology was captured using Nikon 80i 
light microscope.  
 4.3.4 Cell Viability Assay 
Cell viability was measured using trypan blue excision method. T47D cells were cultured 
into 6-well plates until 80% confluent state (high density) or 40% confluent state (low density), 
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corresponding to the conditions in which junctional channel formation was permitted or not, 
respectively. Cells were treated with PQ1 and cisplatin as discussed for the cell morphology 
protocol. Cells floated in the media were collected and cells attached to the wells were 
trypsinized. Two parts of cells were combined together, centrifuged and resuspended. A cell 
suspension was mixed with trypan blue dye and viable cells were examined by the Cellometer 
Auto 2000 (Nexcelom Bioscience, Lawrence, MA, USA). 
 4.3.5 Scrape Load/ Dye Transfer Assay 
T47D cells were seeded on coverslips in 6-well plates and cultured until the confluency 
reached 80% - 100%. Cells were treated with PQ1 (100, 200, and 500 nM) and cisplatin (40 µM) 
alone for 4 hours or sequential combinational treatment, treating PQ1 for 4 hours followed by 
cisplatin for 4 hours. After treatments, cells were rinsed three times with PBS. Then, 2.5 µl 
mixtures of 1% (w/v) Lucifer yellow and 1% (w/v) Rhodamine-dextran were added in the center 
of the coverslips and a scrape was made on the coverslips. The dye solution was left on the 
coverslips for 3 minutes, after which coverslips were washed by PBS for three times. The cells 
were incubated in RPMI medium at 37 °C for 20 minutes, washed by PBS, and then fixed with 
2.5% paraformaldehyde for 10 minutes. Cells were mounted and image of dye transfer was 
captured using Nikon TE2000U fluorescence microscope. The distance of dye transfer from 
cutting site to the farthest visual uptake of dye was measured using ZEN 2010 software.  
 4.3.6 Western Blot Analysis 
T47D cells were cultured in T-25 cm2 flasks until 80% confluent state. Cells were treated 
with PQ1 alone for 28 hours, cisplatin alone for 24 hours, or PQ1 for 4 hours followed by 
addition of cisplatin for 24 hours. Cells without any treatments or DMSO as vehicle were used as 
controls. After treatments, cells were washed with PBS for three times and harvested in lysis 
buffer (Cell Signaling Technology, Danver, MA, USA). Cell lysates were sonicated using Vibra-
Cell sonicator (Sonics & Materials Inc, Danbury, CT, USA) and then centrifuged at 13,000 rpm 
for 30 minutes at 4 °C. After centrifugation, supernatants were collected as whole cell extracts. 
Thirty ug of samples were separated by 4-20% gradient SDS-PAGE for 35 minutes at 200 V, and 
transferred to nitrocellulose membranes (Midwest Scientific, Saint Louis, MO, USA). 
Membranes were blocked with 5% milk for 30 minutes and immunoblotted against protein of 
interest. Immunoreactions using chemiluminescence were visualized by FluorChem E Imaging 
95 
 
Instrument (ProteinSimple, Santa Clara, CA, USA). Intensities of the bands were digitized using 
Un-Scan-It software.  
 4.3.7 Immunofluorescence and Confocal Microscopy 
T47D cells cultured on coverslips in 6-well plates were treated with PQ1 and cisplatin 
alone or in combination as described in Western blot analysis protocol. After treatment, cells 
were rinsed with PBS and fixed with 2% paraformaldehyde for 20 minutes at room temperature. 
Fixed cells were washed 3 times with PBS and then permeabilized with 0.1% Triton X-100 for 8 
minutes. Cells were washed 3 times with PBS again, and blocked with 2.5% BSA in PBS for 1 
hour at room temperature. After blocking, cells were incubated with primary antibodies 
overnight at 4 °C. Samples were incubated with Alexa-conjugated secondary antibodies for 1 
hour at room temperature. DAPI was used to stain nuclei. The slides were mounted by prolong-
antifade reagent (Invitrogen, Camarillo, CA, USA) and sealed. Image was captured using a 
confocal microscope (Carl Zeiss LSM 700 META, Narashige, MN, USA).  
 4.3.8 Statistical Analysis 
Data were statistically analyzed by using student’s t-test. Data presented were expressed 
as mean ± S.D. of at least three independent experiments. Significance was considered at p < 
0.05. 
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 4.4 Results 
 4.4.1 Combinational Treatment of PQ1 and Cisplatin Has a Synergistic Effect on Cell 
Morphology and Proliferation in T47D Cells  
Cisplatin and PQ1 separately have been reported to inhibit cell proliferation and induce 
cell death in breast cancer cells via different mode of action [25, 28]. To address whether 
cisplatin and PQ1 can work synergistically to attenuate cell proliferation, cell morphology and 
proliferation were first examined with the combinational treatment of PQ1 and cisplatin. T47D 
breast cancer cells were treated with PQ1 and cisplatin alone and in combination as PQ1 for 4 
hours followed by addition of cisplatin for 24 hours. Cells without any treatment were used as 
controls. Morphological evaluation showed that both PQ1 and cisplatin changed cell morphology 
and decreased the number of adherent cells (Fig. 4.1). Combinational treatment of PQ1 and 
cisplatin induced more significant morphological changes compared to PQ1 and cisplatin alone. 
Changes including irregular shape, shrinkage, rounding, and detachment were found in PQ1-
pretreated cells in a dose-dependent manner (Fig. 4.1). Combinational treatment of T47D cells 
with 40 µM cisplatin and 200 or 500 nM PQ1 caused a significant change in the morphology 
with less than 50% of cells attached to the bottom of flasks (Fig. 4.1). The proliferation of cells 
was examined by the staining of Ki67, a nuclear protein as a proliferation marker. 24 hours 
treatment of 40 µM cisplatin did not significantly decrease expression of Ki67, indicating that 24 
hours treatment of cisplatin is not sufficient for the inhibition of cell proliferation (Fig. 4.2A, 
4.2B). However, Ki67 staining was decreased in the presence of PQ1 in a dose-dependent 
manner. The combinational treatment of 500 nM PQ1 and 40 µM cisplatin has a significant 
decrease of 23.6% of Ki67 stained cells compared to 92.5% with cisplatin alone and 47.1% with 
PQ1 alone (Fig. 4.2B), indicating a synergistic effect of the combinational treatment on anti-
proliferation. DMSO, a PQ1 vehicle, was used as solvent control, showing no changes on cell 
morphology and proliferation induced by the solvent (Fig. 4.1, 4.2A, 4.2B). These results suggest 
that combinational treatment of PQ1 and cisplatin has a synergistic effect on the changes of cell 
morphology and the inhibition of cell proliferation.  
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Figure 4.1 Synergistic effect of the combinational treatment of PQ1 and cisplatin on cell 
morphology 
T47D cells were treated with PQ1 and cisplatin alone and in combination as indicated. Cells 
without treatment were used as controls. DMSO, a PQ1 vehicle, was used as solvent control. 
Cell morphology was captured using the light microscope under 20X magnification. The scale 
bar is 100 µm in size. 
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Figure 4.2 Synergistic effect of the combinational treatment of PQ1 and cisplatin on cell 
proliferation 
T47D cells were treated with PQ1 and cisplatin alone and in combination. (A) Ki67 staining was 
used to examine cell proliferation under confocal microscope. Red indicates Ki67 and blue 
indicates nuclei stained by DAPI. (B) Percentages of Ki67 in treated cells were calculated and 
the results of each treatment were normalized to its controls. Data were obtained in three 
independent experiments and are represented as the mean ± S.E. * P-value is <0.05 compared to 
control. **P-value is <0.05 compared to cisplatin treatment. *** P-value is <0.05 compared to 
PQ1 treatment. 
 
 4.4.2 PQ1 Increases Cytotoxicity of Cisplatin and the Enhancement Depends on Cell 
Density 
The cytotoxicity of cisplatin in part is due to the bystander effect via GJIC at high cell 
density [24]. Cisplatin-induced cytotoxicity is transduced to neighbor cells through gap junction 
and accordingly induces more cell death under high cell density condition [24]. Since PQ1 has 
been reported as a gap junction enhancer [25], the effect of PQ1 on GJIC raised the possibility 
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that the cytotoxicity of cisplatin could be potentiated by PQ1 via GJIC mediation. Here, 
cytotoxicity of combinational treatment was examined under low and high cell density 
conditions. At low density, cells were well dispersed as single cells without touching the 
neighboring cells, in which a condition with few gap junctions could be formed. However, at 
high density, cells were confluent enough to contact with adjacent cells, allowing the formation 
of gap junctions. Consistent with previous reports [24], the density-dependent toxicity of 
cisplatin was also observed in this study. 24 hours treatment of cisplatin decreased cell viability 
to 85% at low density and 75% at high density, indicating that the cytotoxicity of cisplatin is 
GJIC-dependent (Fig. 4.3A, 4.3B). PQ1 enhanced the cytotoxicity of cisplatin at low and high 
density in a concentration-dependent manner, but the increase of toxic effects at high density is 
more significant (Fig. 4.3A, 4.3B, 4.3C). Compared with cisplatin treatment alone, a 33% 
decrease (75% to 42%) of cell viability was observed in the combinational treatment of cisplatin 
and 500 nM PQ1 under high density condition; whereas, same combinational treatment only 
caused a 24% decrease (85% to 61%) under low density condition (Fig. 4.3A, 4.3B, 4.3C). 
Relative to cisplatin treatment alone, quantification of differences in survival, caused by the 
combinational treatment at different PQ1 concentrations between low and high densities, were 
showed in Fig. 4.3C. PQ1 had a constant effect on cell toxicity regardless on cell density (Fig. 
4.3A, 4.3B). Therefore, the fact that PQ1 had a greater effect on the cytotoxicity of cisplatin at 
high density suggested an enhanced toxic effect of cisplatin via up-regulated GJIC mediated by 
PQ1.   
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Figure 4.3 Effect of PQ1 on cytotoxicity of cisplatin 
T47D cells were treated with PQ1 and cisplatin alone or in combination as indicated. Cell 
viability was measured under high density (A) and low density (B). Graphical presentation of 
three independent experiments is presented with statistical significance. * P-value is <0.05 
compared to control. **P-value is <0.05 compared to cisplatin treatment. *** P-value is <0.05 
compared to PQ1 treatment. (C) Quantification of differences in survival, caused by PQ1 at 
different concentrations in the combinational treatment between low density and high density. 
The viabilities of cells treated with cisplatin alone at high and low density were used as controls. 
Data were obtained in three independent experiments and are represented as the mean ± S.E.  * 
P-value is <0.05 compared to treatment at high density. 
 
 4.4.3 PQ1 Counteracts Cisplatin Inhibition of GJIC and Reduction of Connexins  
Effects of PQ1 on GJIC mediation in the combinational treatment was further 
investigated by examining the activity of the gap junction channels and the expression of 
connexins. From previous findings, 24 hours treatment with PQ1 and cisplatin can cause cell 
death, which subsequently reduces the cell density and gap junctions (Fig. 4.1, 4.3A, 4.3B). 
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Therefore, 4 hours incubation was used to avoid the substantial cell death in the SL/DT 
experiment. T47D cells were treated with PQ1 and cisplatin alone or in combination, and then 
scrap load/dye transfer (SL/DT) was performed. As a gap junction enhancer, PQ1 significantly 
increased GJIC. 500 nM PQ1 increased the distance of dye transfer by 3.7 times compared to 
control (Fig. 4.4B). In contrast, cisplatin treatment alone decreased 60% of the dye transfer from 
cell to cell compared to control, indicating that cisplatin can cause an inhibition of GJIC (Fig. 
4.4B). When cells were incubated with PQ1 prior to cisplatin treatment, a decrease of dye 
transfer induced by cisplatin was rescued (Fig. 4.4A, 4.4B). Combinational treatment of 500 nM 
PQ1 and cisplatin caused a 7.4-fold increase in the distance of dye transfer compared with 
cisplatin treatment alone, as well as a 2.6-fold increase of dye transfer compared to control (Fig. 
4.4B). This implies that not only does 500 nM PQ1 restore cisplatin-inhibited GJIC, but also 
increases the overall GJIC activity in T47D cells. The dye transfer increased with an increase in 
PQ1, suggesting that PQ1-mediated GJIC is concentration dependent (Fig. 4.4A, 4.4B).  
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Figure 4.4 Effect of PQ1 on cisplatin inhibition of GJIC 
T47D cells were treated with PQ1 and cisplatin alone and in combination as indicated. Cells 
without treatment were used as controls. (A) Scrape load/dye transfer assay was performed. 
Green indicates lucifer yellow and red indicates rhodamine-dextran. Gap junction activity is 
examined by measuring the distance of Lucifer yellow dye transfer. Image of dye transfer was 
captured using a fluorescence microscope under 4X magnification. The scale bar is 100 µm in 
size (B) The distance of dye transfer from cutting edge to the farthest cells with the dye uptake 
was measured using Zen 2010 software. The distance of dye transfer for treated cells was 
normalized to the distance of dye transfer of its control group and the graphical presentation of 
three independent experiments was showed with statistical significance. * P-value is <0.05 
compared to control. ** P-value is <0.05 compared to cisplatin treatment.  
 
Gap junctional proteins such as connexin 26 (Cx26), connexin 32 (Cx32), and connexin 
43 (Cx43) are reported to express in human breast cancer cells [29]. Here, levels of these 
connexins were measured by Western blotting. The results showed that 500 nM PQ1 alone 
increased the levels of Cx26, Cx32 and Cx43 by 44%, 55% and 18%, whereas 40 µM cisplatin 
alone showed a decrease in Cx26, Cx32 and Cx43 by 47%, 54%, and 42%, respectively. These 
indicate that the effect of PQ1 and cisplatin treatment is on the level of connexin expression (Fig. 
4.5B). When cells were treated with both PQ1 and cisplatin, the downregulation of connexin by 
cisplatin was reversed by PQ1 (Fig. 4.5A, 4.5B). Relative to cisplatin alone, combinational 
treatment of 500 nM PQ1 and cisplatin significantly increased Cx26, Cx32, and Cx43 by 151%, 
189%, and 74%, respectively (Fig. 4.5B). These results provide evidence that PQ1 can rescue 
cisplatin-induced connexin downregulation and thus subsequently increase the overall GJIC 
activity in T47D cells.  
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Figure 4.5 Effect of PQ1 on cisplatin reduction of connexins 
T47D cells were treated with PQ1 and cisplatin alone and in combination as described. (A) 
Expression of connexin 26 (Cx26), connexin 32 (Cx32), and connexin 43 (Cx43) were examined 
by Western blot analysis. Actin was used as loading control. (B) Graphical presentation of three 
independent experiments shows levels of connexins normalized to control. Pixel intensities of 
protein bands were normalized to pixel intensities of actin, and the results of treated cells are 
normalized to the results of the controls. * P-value is <0.05 compared to control. ** P-value is 
<0.05 compared to cisplatin treatment. 
 4.4.4 Combinational Treatment of PQ1 and Cisplatin Enhances Apoptosis  
Cisplatin is involved in multiple mechanisms after the formation of cisplatin-DNA 
adducts to induce cell death [6]. One mechanism is the induction of apoptosis, a programmed 
cell death [30]. The intrinsic and extrinsic pathways of apoptosis are reported to be activated in 
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response to cisplatin in different cell lines. In human osteosarcoma, cisplatin activates caspase-8, 
the initiator of extrinsic pathway, and subsequently activates caspase-3 to cause cell death [31]. 
However, in many other cell lines (like human SCC-25 squamous carcinoma and cisplatin-
sensitive human testicular cancer cell lines), cisplatin was found to activate the intrinsic pathway 
of apoptosis by releasing cytochrome c and sequentially activating caspase-9 (the intrinsic 
initiator) and caspase-3 [32, 33]. In this study, both intrinsic and extrinsic pathways of apoptosis 
were examined to evaluate the effect of combinational treatment on apoptosis.  
T47D cells were treated with PQ1 and cisplatin individually or in combination as 
described in Materials and Methods. Activation of caspase-8 and -9 were determined by Western 
blotting using antibodies specific to cleaved caspase-9 subunit p35 (caspase-9 p35) and cleaved 
caspase-8 subunit p18 (caspase-8 p18). Our results showed that 24 hours treatment of 40 µM 
cisplatin did not significantly change the level of caspase-9 p35, but slightly increased the level 
of caspase-8 p18 by 13%, indicating that cisplatin induced apoptosis through extrinsic pathway 
within 24 hours (Fig. 4.6A, 4.6B). However, 500 nM PQ1 increased the levels of both cleaved 
caspase-8 and -9, indicating that the activation of both pathways can be induced by PQ1 (Fig. 
4.6A, 4.6B). Interestingly, the combinational treatment of 500 nM PQ1 and 40 µM cisplatin had 
a synergistic effect on both caspase-8 and -9 compared to the treatment of PQ1 or cisplatin alone. 
The relative percentage of caspase-8 p18 expression for the combinational treatment of 500 nM 
PQ1 and 40 µM cisplatin is 185% compared to 113% for cisplatin and 138% for PQ1 (Fig. 
4.6B). Similarly, the combinational treatment also significantly increased the relative percentage 
of caspase-9 p35 expression to 149% compared to 94% for cisplatin and 124% for PQ1 (Fig. 
4.6B).  
To further investigate the intrinsic pathway, expression of two important effectors: Bcl-2, 
an anti-apoptotic protein, and Bax, a pro-apoptotic protein, were examined. The ratio of Bcl-2 to 
Bax is crucial to the release of cytochrome c and subsequently determines if the cell will enter 
the execution phase [34]. Cisplatin is reported to increase the levels of Bax and keep the 
expression of Bcl-2 unchanged in cisplatin-sensitive ovarian cells [35, 36]. However, in some 
cisplatin-resistant ovarian cells, cisplatin-treated cells overexpress Bcl-2 and the high level of 
Bcl-2 protects cells from apoptosis by suppressing Bax [37]. Our results showed that 24 hours 
treatment of 40 µM cisplatin did not significantly change the level of Bax and Bcl-2, compared 
to control (Fig. 4.6B). 200 and 500 nM PQ1 increased the level of Bax, but had no significant 
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effect on Bcl-2. Interestingly, the combinational treatment with PQ1 and cisplatin synergistically 
increased Bax and decreased Bcl-2. Combinational treatment with 500 nM PQ1 and 40 µM 
cisplatin increased the level of Bax to 189.8% compared to 101.9% for cisplatin alone and 
127.7% for PQ1 alone. However, the combinational treatment decreased the level of Bcl-2 to 
23.3% compared to 119.8% for cisplatin alone and 101.6% for PQ1 alone (Fig. 4.6B). The 
results of Bax and Bcl-2 are consistent with the expression of caspase-9 p35, indicating that an 
activation of intrinsic pathway can be induced by the combinational treatment of PQ1 and 
cisplatin. 
Caspase-3 is an executioner at the convergence of multiple apoptotic signaling pathways, 
and activation of caspase-3 is considered to be the last step of apoptosis. The apoptotic effect of 
combinational treatment was further investigated by examining the expression of cleaved 
caspase-3 using confocal microscopy. The staining of cleaved caspase-3 was faint with 40 µM 
cisplatin for 24 hours treatment (Fig. 4.6C). After combinational treatment of 200 or 500 nM 
PQ1 and 40 µM cisplatin, a significant increase of cleaved caspase-3 staining was detected (Fig. 
4.6C). All the results of apoptotic factors suggest that the combinational treatment with PQ1 and 
cisplatin greatly enhanced apoptosis by activating both intrinsic and extrinsic pathways. 
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Figure 4.6 Effect of the combinational treatment of PQ1 and cisplatin onapoptosis 
T47D cells were treated with PQ1 and cisplatin alone and in combination as indicated. Cells 
without treatment were used as controls. (A) Expression of procaspase-9, caspase-9 p35, 
procaspase-8, caspase-8 p18, Bax and Bcl-2 were examined by Western blot analysis. Actin was 
used as loading control. (B) Graphical presentation of three independent experiments shows 
levels of apoptotic factors normalized to control. Pixel intensities of protein bands were 
normalized to pixel intensities of actin, and the results of treated cells are normalized to the 
results of the controls. * P-value is <0.05 compared to control. **P-value is <0.05 compared to 
cisplatin treatment. *** P-value is <0.05 compared to PQ1 treatment. (C) Immunofluorescence 
was performed to examine expression levels of cleaved caspase-3. Red is cleaved caspase-3 and 
blue indicates the nuclei. 
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 4.5 Discussion 
Drug resistance and detrimental side effects are two major problems in platinum-based 
chemotherapy in cancer treatment [38]. Many mechanisms have been reported to contribute to 
cisplatin resistance, including DNA repair, signaling pathway regulation, and tumor 
microenvironment modulation [7]. In addition to these widely-accepted mechanisms which have 
been studied for many years, recent studies found that cisplatin-induced resistance is also 
associated with deficiency in cell-cell communication, the GJIC [7]. Deficiency of GJIC in 
cancer cells and inhibition of GJIC by cisplatin depress the cytotoxicity of cisplatin by 
preventing the cytotoxic molecules or signals from spreading throughout a tumor mass. 
Therefore, strategies to regulate gap junctions are needed to circumvent or decrease cisplatin 
resistance.  
PQ1, a derivative of quinoline, has been reported to enhance GJIC, inhibit cell and tumor 
growth, and increase potential of combinational treatment with tamoxifen in T47D breast cancer 
cells [25, 26]. Studies about the effects of PQ1 on normal tissues further showed that PQ1 
administration can be achieved with low toxicity to normal organs [39]. All these results indicate 
that PQ1 is a promising agent in GJ-based cancer therapy. The present study investigated the 
influence of PQ1 on the cytotoxicity of cisplatin in T47D breast cancer cells. The results showed 
that combinational treatment of PQ1 and cisplatin counteracted the cisplatin-induced inhibition 
of GJIC and decrease of connexins, and subsequently enhanced cytotoxic effects. 
Formation and degradation of gap junctions are dynamic processes with a half-life of 
connexin not exceeding 5 hours [40]. Therefore, short-term pretreatment is used in current 
experiments, examining the effect of communication activity before the degradation of 
connexins. Current study demonstrated that 4 hours treatment is sufficient for PQ1-increasing 
GJIC in T47D cells. To optimize the activation of GJIC by PQ1 as well as minimize the 
inhibition of GJIC by cisplatin, PQ1 was dosed 4 hours prior to cisplatin in the combinational 
treatment.  
The GJIC-mediated bystander effect has been demonstrated to play an important role in 
transferring toxic effects. For example, the application of bystander effect in gene therapy 
showed that after enhancing connexin 43 (Cx43) and GJIC by 8-bromo-cyclic-AMP treatment 
the toxic effect was strengthened by herpes simplex virus thymidine kinase/gancyclovir (HSV-
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TK/GCV) system [17]. Consistent with previous reports [24], our studies showed that the 
toxicity of cisplatin was greater at high density when there is opportunity for gap junctional 
contacts between the cells (Fig. 4.3A, 4.3B), indicating that the cytotoxicity of cisplatin is 
mediated by GJIC. Therefore, inhibition of gap junctional activity and reduction of connexin 
expressions by cisplatin (Fig. 4.4, 4.5) may be in part the cause of low cisplatin cytotoxicity in 
T47D cells. The present data showed that 4 hours pretreatment of PQ1 counteracted inhibition of 
GJIC induced by cisplatin (Fig. 4.4). The direct effect of PQ1 on GJIC suggested a GJIC-
dependent mechanism for the effect of PQ1 on cisplatin cytotoxicity. Moreover, the bystander 
effect of PQ1 on cisplatin reveals that PQ1 has a direct involvement in cisplatin toxicity in high 
cell density cultures (Fig. 4.3C).  
In addition to GJIC-dependent mechanism, PQ1 also adds tumor-suppressing component 
to the combinational treatment by GJIC-independent mechanisms. PQ1 inhibited cell 
proliferation, decreased cell viability and induced apoptosis (Fig. 4.2, 4.3, 4.6). The findings also 
showed that the cytotoxicity of PQ1 is cell density independent, supporting that PQ1 can mediate 
cytotoxic effect via GJIC-independent mechanism. In primary breast tumors, Cx26 has been 
reported to affect cellular process by GJIC-independent functions [41]. In literature, genistein 
and quercetin increase Cx43 and suppress breast cancer cell proliferation in a GJIC-independent 
way [42]. All these studies demonstrate that connexins can function as tumor suppressors via 
GJIC-independent mechanism. Therefore, the GJIC-independent cytotoxicity of PQ1 may be 
related to the overexpression of connexins by PQ1. In the combinational treatment, Cx26, Cx32, 
and Cx43 protein levels were increased in the presence of PQ1 (Fig. 4.5). 500 nM of PQ1 not 
only rescued cisplatin-induced decreases of Cx26 and Cx32, but also increased Cx26 and Cx32 
to a level higher than control (no treatment) (Fig. 4.5). Cell viability results showed that PQ1 
increased toxicity of cisplatin at low cell density when there is no gap junction formation (Fig. 
4.3B). Current findings established a GJIC-independent mechanism for the effect of PQ1 on 
cisplatin-mediated response.  
This report showed that combinational treatment of PQ1 and cisplatin had a synergistic 
effect on apoptosis by activating both the intrinsic and extrinsic apoptotic pathways (Fig. 4.6A, 
4.6B). Both the bystander effect and GJIC-independent mechanism may be responsible for the 
apoptosis induction. The cisplatin-DNA adducts have been reported to activate caspases and 
induce apoptosis [5]. Therefore, one hypothesis related to bystander effect is that PQ1 restores 
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gap junction channels in the combinational treatment, allowing increasing amounts of cisplatin-
induced cytotoxic signals to enter the neighboring cells, which accordingly trigger the apoptosis 
by a GJIC-dependent mechanism. The other hypothesis related to GJIC-independent mechanism 
depends on connexins. Expressions of Cx26 and Cx43 have been reported to be correlated with 
the expression level of the proapoptotic factor Bax, suggesting that connexins may participate in 
apoptotic pathways [43]. Therefore, the second hypothesis is that apoptosis induced by 
combinational treatment may attribute to the overexpression of connexins in the presence of 
PQ1.  
Cisplatin resistance has been widely reported in many cancer treatments, including 
testicular, ovarian, and cervical cancers. Studies of gap junctions revealed that GJIC and 
connexin expressions are dramatically reduced in these cancer cells. In ovarian cancer cell lines, 
expressions of Cx26 and Cx43 are reduced [44]. Chemosensitivity studies found that loss of 
Cx43 proteins may be associated with sensitivity to anticancer drugs [44]. In dysplastic 
ectocerivix, a premalignant lesion which can turn cancerous, Cx26, Cx30 and Cx43 display a 
loss of expression [45]. The characteristic loss of connexins in these cancers as well as the results 
of this study implies that the application of the combinational treatment of PQ1 and cisplatin can 
be expanded to the therapy of various cisplatin-resistant cancers.  
The present study showed that combinational treatment of PQ1 and cisplatin activates the 
activity of gap junction channels, increases the expression of connexins, and potentiates the 
cytotoxicity of cisplatin by inducing apoptosis. PQ1 is a promising molecule for combinational 
therapy aimed at potentiating cisplatin efficacy, decreasing cisplatin resistance and reducing side 
effects.   
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Chapter 5 - The Effect of the PQ1 Anti-breast Cancer Agent on 
Normal Tissues 
 5.1 Abstract 
Gap junctions are intercellular channels connecting adjacent cells, allowing cells to 
transport small molecules. Loss of gap junctional intercellular communication (GJIC) is one of 
the important hallmarks of cancer. Restoration of GJIC is related to the reduction of 
tumorigenesis and increase of drug sensitivity. Previous reports showed that PQ1, a quinoline 
derivative, increases GJIC in T47D breast cancer cells, and subsequently attenuates xenograft 
breast tumor growth. Combinational treatment of PQ1 and tamoxifen can lower the effective 
dose of tamoxifen in cancer cells. In this study, effects of PQ1 were examined in normal 
C57BL/6J mice, evaluating the distribution, toxicity and adverse effects. Distribution of PQ1 
was quantified by HPLC and mass spectrometry. Expressions of survivin, caspase-8, cleaved 
caspase-3, aryl hydrocarbon receptor (AhR), and gap junction protein, connexin 43 (Cx43), were 
measured using Western blot analysis. Our results showed that PQ1 absorbed and distributed to 
vital organs within one hour and the level of PQ1 diminished after 24 hours. Furthermore, PQ1 
increased the expression of survivin, while decreased the expression of caspase-8 and caspase-3 
activity. Interestingly, expression of AhR increased in the presence of PQ1, suggesting that PQ1 
may be involved in AhR-mediated response. Previously, PQ1 caused an increase in Cx43 
expression in breast cancer cells; however, PQ1 induced a decrease of Cx43 in normal tissues. 
Hemotoxylin and eosin staining of the tissues showed no histological change between treated 
and untreated organs. Our studies indicate that PQ1 administration by oral gavage can be 
achieved with low toxicity to normal vital organs.  
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 5.2 Introduction 
Gap junctional intercellular communication (GJIC) plays an important role in controlling 
cell growth, regulating cell differentiation, and maintaining homeostasis in normal cells and 
tissues [1, 2]. Gap junction is a hydrophilic channel which is formed by transmembrane proteins, 
connexins [3]. Six connexins oligomerize into a hexameric structure known as connexon. 
Connexon at the plasma membrane may stand alone as a hemichannel or may dock with another 
connexon of an adjacent cell to form a gap junction [4]. The gap junction channel allows cells to 
exchange small molecules of less than 1.2 kDa in size including small metabolites, electrical 
signals, and secondary messengers including cAMP, Ca2+, K+, etc [5]. This maintenance of 
communication keeps cells at homeostasis. Literature shows that mutations in connexin genes or 
deficiency in GJIC are related to various human diseases, such as deafness, peripheral 
neuropathy, skin disorders, cataracts, and even cancers [6, 7].  
Diminished connexin expression and deficiency in GJIC are considered to be two 
characteristics of tumorigenesis [8, 9]. Although it is still controversial about the function of 
connexins in invasion, intravasation, extravasation and metastasis, it has been widely accepted 
that connexins are tumor suppressors due to both the GJIC-dependent and GJIC-independent 
mechanisms [10-14]. Restoration or/and activation of GJIC in cancer cells are suggested to have 
the ability to reduce cancer cell proliferation and tumor growth [15, 16]. In addition to directly 
suppressive function, upregulation of GJIC in cancer cells is also important to increase efficacy 
of anticancer drugs. Re-establishment of GJIC is helpful in the delivery of drug or pro-drug 
throughout a tumor, and subsequently mediates bystander effect, a mechanism by which 
cytotoxic molecules are transported from a treated cell to a neighboring cell [13]. This 
mechanism has demonstrated to be an effective way to potentiate drug effect. The application of 
bystander effect in gene therapy showed that after enhancing connexin 43 (Cx43) and GJIC by 8-
bromo-cyclic-AMP treatment, gene therapy effect was strengthened by herpes simplex virus 
thymidine kinase/gancyclovir (HSV-TK/GCV) system [17]. Besides gene therapy, bystander 
effect is also responsible for improving radiation therapy and chemotherapy [18, 19]. Therefore, 
development of novel agents or methods to enhance or restore GJIC in cancer cells is a new 
research strategy in cancer treatment.  
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PQ1 is a quinoline derivative which has been reported as a gap junction enhancer in 
T47D breast cancer cells. Previously, PQ1 increased GJIC in T47D cells, whereas it had no 
effect on GJIC in normal human mammary epithelial cells (HMECs) [20]. One µM of PQ1 
decreased cell viability to 50% in T47D cells and attenuated 70% of xenograft tumor in nude 
mice [20]. Combinational treatment of PQ1 and tamoxifen showed that PQ1 potentiated the 
effect of tamoxifen in T47D cells [21]. All these studies imply therapeutic potential of PQ1 in 
breast cancer treatment. However, data of PQ1 on normal tissues are needed prior to preclinical 
trial of PQ1.  
In this study, effect of PQ1 was evaluated in healthy C57BL/6J mice. Drug distribution to 
vital organs was determined and effect of PQ1 on apoptosis was analyzed. We also examined the 
expression of aryl hydrocarbon receptor (AhR), a ligand-activated transcription factor that 
regulates transcription and activity of several important drug-metabolizing enzymes. Further 
analysis using histological observation of PQ1-treated tissues showed no alteration in structure 
change. Our results showed that the distribution of PQ1 via oral administration in mice can be 
assessed and low toxicity in vital organs was found.    
121 
 
 5.3 Material and Methods 
 5.3.1 PQ1 
PQ1. A quinoline derivative, PQ1, was obtained as described by Shi et al. [22]. 
 5.3.2 Animals 
Female C57BL/6J mice were purchased from Jackson Laboratories (Bar Harbor, Maine). 
All mice were housed together in a temperature controlled environment (72°F) with a 12-hour 
light-dark cycle and unlimited access to standard mouse chow and water. Five-week-old mice, 
with an average weight of 24 grams, were used. Twenty-five mg/kg PQ1 was administered by 
oral gavage to each animal. Animal care and use protocols were approved by the Institutional 
Animal Care and Use Committee (IACUC) at Kansas State University, following NIH 
guidelines. 
 5.3.3 Extraction of PQ1 from Organs   
Organs were diced into small pieces and diluted with 4 ml of deionized water and 10 ml 
of a solution of 9:1 ratio of ethyl acetate and 1-propanol. Tissue mixture was sonicated for 40 
minutes, and the organic layer was separated from a separatory funnel. The aqueous layer was 
extracted twice with 10 ml of a 9:1 mixture of ethyl acetate and 1-propanol. The organic layers 
were combined, washed with 5 ml of brine, dried over anhydrous MgSO4, and concentrated to 
dryness on a rotary evaporator. The residue was diluted with 1 ml of 1-propanol, filtered through 
a 0.2 µm filter disc (PTFE 0.2 µm, Fisherbrand), and analyzed using high-performance liquid 
chromatography (HPLC) and mass spectrometry as described below. 
 5.3.4 Quantification of PQ1 in Tissue Extracts using HPLC 
HPLC analysis was carried out on a Varian Prostar 210 with a UV-Vis detector and a 
reverse phase column (250 x 21.20 mm, 10 micron, Phenomenex Inc.). A flow rate of 4 ml/min 
and detection wavelength of 254 nm were used. A gradient elution of solvent A, containing 
deionized water and 0.01% of trifluoroacetic acid, and solvent B, containing acetonitrile and 
0.01% of trifluoroacetic acid, was applied for the analysis. 1,2,4,5-Benzenetetracarboxylic acid 
(BTA) was used as an internal standard to quantify the amount of PQ1 in the tissue extracts. 
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Solutions of 100 μl of various mixtures of authentic PQ1 and BTA were injected into a HPLC 
instrument, the peak areas corresponding to PQ1 and BTA were integrated from the HPLC 
chromatogram, and the ratios of the peaks were obtained.  Results of the ratios of HPLC peak 
areas and ratios from PQ1 and BTA concentrations were plotted, and a linear correlation line was 
obtained from the graph. Hence using this correlation diagram, the ratio of HPLC peak areas of 
PQ1 and BTA from tissue extract and the added known amount of BTA to the tissue extract, the 
amount of PQ1 in the tissue extract was determined. Moreover, the peak that has the same 
retention time as that of PQ1 from the injection of the tissue extract was collected, and its mass 
was determined using a mass spectrometer. The mass spectrum acquired from collected peak of 
PQ1 from the tissue extract was identical to that of the authentic PQ1 mass spectrum. Hence, the 
molecular identity of PQ1 in the tissue extract was verified by mass spectrometry. 
 5.3.5 Mass Spectroscopy  
An Applied Biosystem API 2000 LS/MS/MS mass spectrometer was used in the analysis. 
The eluent corresponding to PQ1 peak from the HPLC was collected and injected into the mass 
spectrometer. A mass of 406 corresponding to M+1 of PQ1 was found in the mass spectra, and 
the fragmentation pattern of this M+1 mass is identical to that of authentic PQ1. 
 5.3.6 Western Blot Analysis 
Organs from treated or untreated mice were collected and homogenized with lysis buffer 
(Cell Signaling Technology, Inc, Danver, MA) using Vibra-Cell sonicator (Sonics & Materials 
Inc, Danbury, CT). The mixture was centrifuged at 13,000 rpm (15,700 x g using an Eppendorf 
centrifuge 5415R with rotor F-45-24-11) for 30 minutes at 4°C, and the supernatant was 
collected. Total protein concentration was determined by a Bio-Rad protein assay kit. Forty µg 
of protein extract were separated by 4 - 20% sodium dodecylsulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) for 35 minutes at 200 Volts and proteins separated were transferred 
to nitrocellulose membrane. The membrane was immunoblotted against protein of interest. The 
goat anti-survivin antibody and mouse anti-caspase-8 antibody were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA). The rabbit anti-cleaved caspase-3 and rabbit anti-connexin 43 
antibodies were obtained from Cell Signaling Technology (Danvers, MA). The rabbit anti-AhR 
and rabbit anti-actin antibodies were purchased from Sigma-Aldrich (St. Louis, MO). 
Immunoreactions using chemiluminescence were visualized by FluoChem E Imaging Instrument 
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(Cell Biosciences, Inc, Santa Clara, CA). Intensities of the bands were digitized using Un-Scan-It 
software.  
 5.3.7 Hematoxylin and Eosin (H&E) Staining 
H&E staining was performed on paraffin-embedded tissues by following standard 
protocol. Five µm sections were dewaxed and rehydrated in xylene and decreasing ethanol 
concentrations to water. Sections were stained with hematoxylin and eosin and mounted for 
microscopic imaging. 
 5.3.8 Statistical Analysis  
Pixel intensities of protein bands were normalized to pixel intensities of loading control 
protein, actin or GAPDH. All protein expression data presented were expressed as mean ± S.D. 
of at least three independent experiments from different animals. Significant differences were 
analyzed by comparing the data between treated animals and control (untreated) animals. 
Significance was considered at p < 0.05 using student’s t-test.  
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 5.4 Results 
 5.4.1 Distribution of PQ1  
Examination of distribution is important for the development of PQ1 as an anti-cancer 
drug. Twenty-five mg/kg of PQ1 were administered to five-week-old female C57BL/6J mice by 
oral gavage. The total amount of PQ1 administered to each animal was defined as 100%. One-
hour post-treatment the majority of PQ1 was detected in liver and brain at levels of 10% and 5% 
of the total amount administered, respectively. PQ1 was at a low detectable level in the heart 
with 1%, lung with 1.5%, kidney with 1%, and uterus with 2.5% (Fig. 5.1A). Interestingly, PQ1 
distribution changed after 12 hours of administration. The percentage of PQ1 in liver decreased 
from 10% to 5%, and percentage of PQ1 in brain dropped from 5% to 2%. On the contrary, PQ1 
in kidney increased from 1% to 3%, indicating a shift of PQ1 from liver to kidney had occurred. 
Amounts of PQ1 in heart, lung and uterus remained consistent at 12 hours of administration (Fig. 
5.1B). After 24-hour treatment, no PQ1 was found in brain and heart. Percentage of PQ1 
decreased to 3% in liver and 1% in kidney. The average percentage of PQ1 in uterus stayed at 
3%. PQ1 in lung had a slight increase from 1.5% to 2.6% at 24-hour time point (Fig. 5.1C).  
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Figure 5.1 PQ1 distribution in mice 
B 
C 
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Mice, treated with 25 mg/kg of PQ1, were sacrificed at 1hr (A), 12hrs (B), and 24hrs (C). The 
total amount of PQ1 administered to each animal was defined as 100%. Percentages of PQ1, 
normalized to total amounts of PQ1 in brain, heart, lung, liver, kidney, and uterus, were 
presented. Data of each experiment were obtained from four mice. Data points represent the 
percentage of PQ1 in an organ of each mouse, and the dash lines show the average of PQ1 in 
four mice.  
 5.4.2 Effect of PQ1 on Apoptosis in Normal Tissues 
Apoptosis is a programmed cell death, an important event in homeostasis of healthy 
organs [23, 24]. Drugs, affecting apoptosis in healthy organs, are concerned, because they may 
cause apoptosis-related side effects [25]. Cell proliferation or cell death often depends on the 
balance of pro- and anti-apoptotic factors. Thus, expressions of survivin, an anti-apoptotic factor, 
and caspases, pro-apoptotic proteins, were evaluated. Two specific members of caspase family 
were examined in the presence of PQ1: cleaved caspase-3 is the checkpoint protein of both 
intrinsic and extrinsic apoptotic pathways and caspase-8 is the key reporter of extrinsic apoptotic 
pathway [26].  
The results showed that the level of survivin increased in PQ1-treated organs, while both 
cleaved caspase-3 and caspase-8 decreased in these organs (Fig. 5.2A, 5.2B, 5.2C). The level of 
survivin increased by 14% in liver, 28% in heart, and 44% in lung at 1 hour after PQ1 
administration, compared to controls. These effects are consistent with the detected level of PQ1. 
Interestingly, the level of survivin in these organs was reduced to the same level as the controls 
at 24-hour time point. In brain and kidney, there were no detectable changes in survivin 
expression at any time point. Uterus was the only exception in which survivin decreased more 
than 25% after PQ1 treatment (Fig. 5.2A). As for caspase 8 expression, brain, heart, lung, liver, 
and uterus of the treated animals had a slight decrease in expression ranging from 12% to 37% 
compared to untreated animals; however, there was no significant change in the kidney (Fig. 
5.2B). Cleaved caspase-3 was only detected in the uterus, liver, and lung of untreated animals; 
thus, the change in cleaved caspase-3 upon PQ1 treatment was measured in these three organs.  
A significant decrease ranging from 37% to 45% of cleaved caspase-3 at 12-hour post-treatment 
was observed, compared to the control (Fig. 5.2C). Results of caspases and survivin suggest that 
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PQ1 inhibits pro-apoptotic factors and promotes anti-apoptotic proteins in different normal 
organs. 
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Figure 5.2 Effect of PQ1 on apoptosis in normal tissues. 
Vital organs from PQ1-treated and untreated animals were subjected to Western blot analysis, 
examining the effect of 1hr, 12hrs, and 24hrs treatments of PQ1 on the levels of survivin (A), 
caspase-8 (B), and cleaved caspase-3 (C). Immunblotting images and graphical data are 
presented. “C” indicates the control animals without treatment and “T” indicates PQ1-treated 
animals. Two fragments of activated caspase-3 were detected in uterus and liver. The upper band 
is 19 kDa fragment and the lower band is 17 kDa fragment. In the bar graph, pixel intensities of 
protein bands were normalized to pixel intensities of loading control protein, actin, and the 
results of treated animals are normalized to the results of control animals. Graphical presentation 
of three experiments are presented with ±SD and statistical significance, *p<0.05.  
 5.4.3 Effect of PQ1 on AhR Levels in Normal Tissues 
Aryl hydrocarbon receptor (AhR) is a transcriptional factor involved in the metabolic 
pathway of aromatic hydrocarbon compounds [27]. The main adaptive response of AhR is the 
binding of AhR and hydrocarbon compounds, inducing metabolizing enzymes that are involved 
in its metabolic pathway [27]. Aromatic hydrocarbon compounds have been demonstrated to 
trigger AhR-mediated pathway for its metabolism; thus, the effect of PQ1, an aromatic 
hydrocarbon compound, on AhR was examined.    
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The results showed that the level of AhR in brain, heart, and liver increased significantly 
at 12-hour post-PQ1 treatment, 161%, 167%, and 124% compared to controls, respectively; 
however, there was a delay in detecting AhR in the kidney. A 114% AhR was detected in the 
kidney at 24-hour point (Fig. 5.3A). From the drug/tissue distribution data, the amounts of PQ1 
peaked at 1 hour in brain, heart and liver, but peaked at 12-hour point in kidney (Fig. 5.1A, 
5.1B). These suggest that there is a time-delay response in AhR in these organs. Interestingly, the 
level of AhR fluctuated from 117% at 1-hour of dosing to 63% at 12-hour of dosing. 
Furthermore, only 57%, 61%, and 54% of AhR were detected in the treated uterus at 1-, 12-, and 
24-hour time points, respectively, compared to controls (Fig. 5.3A). An early onset of AhR 
downregulation after PQ1 administration implies that PQ1 might be involved in a different mode 
of action in the uterus. At 1 hour of PQ1 administration, level of AhR proportionally changed 
along with the amount of PQ1 in liver, indicating a direct dependent function of AhR to PQ1 in 
liver (Fig. 5.3B). The data demonstrated that PQ1 can trigger the change in expression of AhR in 
brain, heart, liver, and kidney.  
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Figure 5.3 Effect of PQ1 on AhR levels in normal tissues. 
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(A) Western blot analysis, examining the effect of 1hr, 12hrs, and 24hrs treatments of PQ1 on 
the level of AhR, was performed. Mice without PQ1 treatment were used as control. 
Immonoblotting images and graphical data are presented. “C” indicates the control animals 
without treatment and “T” indicates PQ1-treated animals. In the bar graph, pixel intensities of 
protein bands were normalized to pixel intensities of loading control protein, actin. Graphical 
presentation of three experiments are presented with ±SD and statistical significance, *p<0.05. 
(B) The level of AhR changes proportionally along with the amounts of PQ1 in liver after 1-hour 
treatment. Immnoblotting images are also shown above the graph. A line indicates percentage of 
PQ1 normalized to the amount of PQ1 in the liver of a corresponding animal. AhR level 
normalized to control group are shown by the bar graph. All the data have been normalized with 
the body weight of each mouse as well. 
 5.4.4 Effect of PQ1 on Connexin in Normal Tissues 
Since PQ1 has been shown to enhance GJIC [20] and increase Cx43 expressions (data not 
shown) in breast cancer cells, expressions of Cx43 in PQ1-treated and -untreated organs was 
measured. Cx43 was detected in heart, brain, and lung in the absence of PQ1 treatment; however, 
the level of Cx43 diminished in all PQ1-treated organs. A statistically significant decrease of 
31% compared to control was found at 24-hour point in the heart. A constant level of Cx43 in the 
lung was observed at all-time points. Interestingly, level of Cx43 in brain gradually declined over 
time (Fig. 5.4). These results suggest that the function of PQ1 in normal cells may involve in 
different mode of action as compared to previously observed in cancer cells.  
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Figure 5.4 Effect of PQ1 on connexin 43 expression in normal tissues. 
Brain, heart and lung from treated and untreated mice were subjected to Western blot analysis, 
examining the effect of 1hr, 12hrs, and 24hrs treatments of PQ1 on the level of connexin 43. 
Mice without PQ1 treatment were used as control. Both immunoblotting images and graphical 
data are presented. Both the phosphorylated Cx43 and unphosphorylated Cx43 were detected in 
heart. The upper band indicates the phosphorylated Cx43, and the lower band indicates the 
unphosphorylated Cx43. Pixel intensities of protein bands were normalized to pixel intensities of 
loading control protein, GAPDH, in the bar graph. Graphical presentation of three experiments 
are presented with ±SD and statistical significance, *p<0.05.   
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 5.4.5 Histological Analysis of Normal Tissues  
Liver is an important organ in drug metabolism. Hematoxylin and eosin (H&E) staining 
of PQ1-treated organs was performed. All twenty-four mice were assessed grossly or 
microscopically for histological changes. Histological results showed that PQ1-treated liver 
remained unchanged compared to control, which indicate no observable toxicity of PQ1 to liver 
at the treated dosage and time (Fig. 5.5A). Other tissues including heart, adrenal gland, kidney, 
and reproductive tract were also examined and no histological change was observed (Fig. 5.5B). 
Twenty-one of the histologically PQ1-treated mice had no evidence of hemorrhage or 
inflammatory cells. These mice had no histological evidence of lesion compared to control mice 
without PQ1 treatment at any time point. 
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Figure 5.5 A H&E staining of whole organs. 
(A) PQ1-treated tissues were examined by H & E staining. A. Liver sections from untreated 
animal (a) and PQ1-treated animals at 1hr (b), 12hrs (c), and 24hrs (d) are presented. Toxicity of 
PQ1-treated liver was examined by H & E staining using 40X magnification. Histological results 
showed that PQ1-treated liver had no change compared to control. (B) Histology of PQ1-treated 
animals for heart (a), adrenal gland (b), and reproductive tract (d) were observed under 4X 
magnification, and kidney (c) was observed under 10X magnification. The results show no 
histological alteration in the treated animals compared to control. 
B 
136 
 
 5.5 Discussion 
Cancer is a complicated disease with multiple deregulation pathways, necessitating 
cancer treatment with multiple and combinational approaches [28]. The deficiency of GJIC in 
cancer cells adds to the complexity of cancer treatment in which the lack of drug transfer to the 
surrounding area creates challenges to cancer therapy [14]. Some anticancer drugs are reported to 
inhibit GJIC and reduce connexin expression [29, 30]. Hence, restoration of GJIC in cancer cells 
is a focal point in combinational treatment by potentiating the effect of anticancer drugs. In 
addition to combinational treatment, overexpression of connexin and activation of GJIC also 
play a suppressive role to tumors [13]. Therefore, the development of molecules and agents 
increasing the connexin expression and GJIC can be a useful therapeutic strategy in cancer 
therapy.  
Quinolines are known for their anticancer effects by targeting tumor hypoxia and 
modulating multidrug resistance [31, 32]. Previous reports showed that PQ1, a quinoline 
derivative, enhances GJIC, inhibits cell and tumor growth, and increases potential of the 
combinational treatment with tamoxifen in T47D breast cancer cells [20, 21]. Therefore, the 
current study provides data of drug/tissue distribution and examines key factors of apoptotic 
pathways in normal mice.  
Oral gavage, a desirable and safe route of administration, is used in this study. Uptake of 
any drug is depending on the rate of blood flow; thus, the level of PQ1 was evaluated in five vital 
organs (brain, heart, lung, kidney, and liver) that have high rate of blood flow. PQ1 was 
measured in each vital organ after oral administration. The effective dosage of PQ1 falls in nM 
range in cells and xenograft tumors [20]. To investigate the toxicity in normal organs, a higher 
concentration of PQ1 was administered at 25 mg/kg body weight, which is equivalent to 47.7 
µM. The concentrations of PQ1 in organs examined were more than 20-fold higher than the 
effective dosage. PQ1 was detected in all tested organs after 1-hour treatment and diminished at 
24-hour post-treatment, suggesting that PQ1 can be eliminated or excreted after 24 hours (Fig. 
5.1). The highest concentrations of PQ1 were found in the liver and kidney at different time 
points (Fig. 5.1A and 5.1B). A high percentage of PQ1 was detected in the brain at 1 hour. This 
detectable level may be due to the processing of tissue in which PQ1 in the blood vessels could 
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not be excluded during the whole tissue extract (Fig. 5.1A). Our results show that PQ1 can be 
absorbed, distributed to vital organs, and metabolized in C57B/6J mice.   
A serious side effect of therapeutic drugs is a potential activation of apoptosis pathway in 
normal cells. For example, diarrhea, a common side effect of chemotherapy, is partly caused by 
induced apoptosis in normal cells of the small intestinal epithelium [25]. It has also been reported 
that both chemotherapeutic drugs and irradiation can induce apoptosis in normal thymocytes [33, 
34]. In this report, the presence of PQ1 via oral gavage caused a decrease in cleaved caspase-3 
and an increase in survivin of normal tissues, indicating the inactivation of apoptosis (Fig. 5.2A, 
5.2C). Further study of extrinsic apoptotic pathway showed a decrease of caspase-8 after 
treatment of PQ1, which further elucidates that PQ1 cannot activate the extrinsic pathway of 
apoptosis in normal tissues (Fig. 5.2B). The effect on apoptosis in normal organs indicates a 
minor, apoptosis-related side effect caused by PQ1. Interestingly, PQ1 increased caspase-3 
cleavage [20] and the level of caspase-8 protein in T47D cells. The opposing aspect of PQ1 on 
apoptosis in cancer cells compared to normal tissues implies that PQ1 may have a different 
mechanism in cancer cells. The difference between cancer and normal cells is also shown by the 
function of PQ1 on connexin expression. PQ1 enhances GJIC [20] and increases connexin 
expression in T47D breast cancer cells; however, it decreases the expression of Cx43 in a normal 
heart, brain, and lung (Fig. 5.4). PQ1 mechanism of opposing effects in normal and cancer cells 
is not clear. Further studies are needed to clarify the causes of anti-tumor effects. 
AhR, a ligand-dependent transcription factor involved in the transcription of many 
important drug-metabolizing enzymes [35], is widely expressed in rodent and human tissues 
[36]. Increase of AhR protein level in PQ1-treated mice was observed in vital organs, indicating 
the possible involvement of PQ1 in the activation of ligand-dependent transcription of AhR 
pathway (Fig. 5.3A). The proportional relation between AhR expression and detected level of 
PQ1 in liver at 1 hour showed a direct impact of PQ1 on AhR expression. However, AhR was 
decreased by PQ1 treatment in the lung compared to control. Previous report demonstrated that 
increase of AhR was found in the early stage of lung adenocarcinoma [37], suggesting that low 
level of AhR in PQ1-treated lung is due to tissue specificity. Furthermore, increase of AhR in 
PQ1-treated organs implies that PQ1 is involved in AhR-mediated pathway. Further analysis of 
gene regulation and enzyme activities in AhR-mediated pathways is needed to elucidate the 
metabolism of PQ1.  
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Gap junction has been studied for more than forty years. Until recently, the involvement 
of gap junction in cancer has been reported and widely discussed. Although several molecules 
have been developed to modulate different levels of gap junctional proteins and GJIC [13], none 
of these molecules has reached clinical trials for the treatment of cancer. Our present findings 
support the notion that PQ1 is a promising anti-breast cancer candidate and may serve as a lead 
compound for drug development.   
 Acknowledgments 
We gratefully acknowledge the financial support from the Center for Basic Cancer 
Research at Kansas State University, NIH R15CA152922 and NIH P30-RR030926. We also 
acknowledge Keshar Prasain and Thi D.T. Nguyen for performing HPLC and Mass spectroscopy 
experiments.  
139 
 
 References 
1.  Loewenstein WR (1979) Junctional intercellular communication and the control of growth. 
Biochim Biophys Acta 560: 1-65. 
2.  Vinken M, Vanhaecke T, Papeleu P, Snykers S, Henkens T, et al. (2006) Connexins and 
their channels in cell growth and cell death. Cell Signal 18: 592-600. 
3.  Spanakis SG, Petridou S, Masur SK (1998) Functional gap junctions in corneal fibroblasts 
and myofibroblasts. Invest Ophthalmol Vis Sci 39: 1320-1328. 
4.  Salameh A (2006) Life cycle of connexins: regulation of connexin synthesis and 
degradation. Adv Cardiol 42: 57-70. 
5.  Kumar NM,Gilula NB (1996) The gap junction communication channel. Cell 84: 381-388. 
6.  Wei CJ, Xu X, Lo CW (2004) Connexins and cell signaling in development and disease. 
Annu Rev Cell Dev Biol 20: 811-838. 
7.  Cronier L, Crespin S, Strale PO, Defamie N, Mesnil M (2009) Gap junctions and cancer: 
new functions for an old story. Antioxid Redox Signal 11: 323-338. 
8.  Pointis G, Fiorini C, Gilleron J, Carette D, Segretain D (2007) Connexins as precocious 
markers and molecular targets for chemical and pharmacological agents in carcinogenesis. 
Curr Med Chem 14: 2288-2303. 
9.  Laird DW, Fistouris P, Batist G, Alpert L, Huynh HT, et al. (1999) Deficiency of 
connexin43 gap junctions is an independent marker for breast tumors. Cancer Res 59: 
4104-4110. 
10.  Li Q, Omori Y, Nishikawa Y, Yoshioka T, Yamamoto Y, et al. (2007) Cytoplasmic 
accumulation of connexin32 protein enhances motility and metastatic ability of human 
hepatoma cells in vitro and in vivo. Int J Cancer 121: 536-546. 
11.  Ezumi K, Yamamoto H, Murata K, Higashiyama M, Damdinsuren B, et al. (2008) Aberrant 
expression of connexin 26 is associated with lung metastasis of colorectal cancer. Clin 
Cancer Res 14: 677-684. 
12.  Lin JH, Takano T, Cotrina ML, Arcuino G, Kang J, et al. (2002) Connexin 43 enhances the 
adhesivity and mediates the invasion of malignant glioma cells. J Neurosci 22: 4302-4311. 
13.  Kandouz M,Batist G (2010) Gap junctions and connexins as therapeutic targets in cancer. 
Expert Opin Ther Targets 14: 681-692. 
140 
 
14.  Naus CC,Laird DW (2010) Implications and challenges of connexin connections to cancer. 
Nat Rev Cancer 10: 435-441. 
15.  Eghbali B, Kessler JA, Reid LM, Roy C, Spray DC (1991) Involvement of gap junctions in 
tumorigenesis: transfection of tumor cells with connexin 32 cDNA retards growth in vivo. 
Proc Natl Acad Sci U S A 88: 10701-10705. 
16.  Loewenstein WR,Rose B (1992) The cell-cell channel in the control of growth. Semin Cell 
Biol 3: 59-79. 
17.  Van Dillen IJ, Mulder NH, Vaalburg W, de Vries EF, Hospers GA (2002) Influence of the 
bystander effect on HSV-tk/GCV gene therapy. A review. Curr Gene Ther 2: 307-322. 
18.  Prise KM,O'Sullivan JM (2009) Radiation-induced bystander signalling in cancer therapy. 
Nat Rev Cancer 9: 351-360. 
19.  Merle P, Morvan D, Caillaud D, Demidem A (2008) Chemotherapy-induced bystander 
effect in response to several chloroethylnitrosoureas: an origin independent of DNA 
damage? Anticancer Res 28: 21-27. 
20.  Gakhar G, Ohira T, Shi A, Hua DH, Nguyen TA (2008) Antitumor effect of substituted 
quinolines in breast cancer cells. Drug Dev. Res. 69: 526-534. 
21.  Gakhar G, Hua DH, Nguyen TA (2010) Combinational treatment of gap junctional 
activator and tamoxifen in breast cancer cells. Anticancer Drugs 21: 77-88. 
22.  Shi A, Nguyen TA, Battina SK, Rana S, Takemoto DJ, et al. (2008) Synthesis and anti-
breast cancer activities of substituted quinolines. Bioorg Med Chem Lett 18: 3364-3368. 
23.  Collins MK,Lopez Rivas A (1993) The control of apoptosis in mammalian cells. Trends 
Biochem Sci 18: 307-309. 
24.  Franceschi C (1989) Cell proliferation, cell death and aging. Aging (Milano) 1: 3-15. 
25.  Tamaki T, Naomoto Y, Kimura S, Kawashima R, Shirakawa Y, et al. (2003) Apoptosis in 
normal tissues induced by anti-cancer drugs. J Int Med Res 31: 6-16. 
26.  Elmore S (2007) Apoptosis: a review of programmed cell death. Toxicol Pathol 35: 495-
516. 
27.  Hankinson O (1995) The aryl hydrocarbon receptor complex. Annu Rev Pharmacol 
Toxicol 35: 307-340. 
28.  Xia D, Moyana T, Xiang J (2006) Combinational adenovirus-mediated gene therapy and 
dendritic cell vaccine in combating well-established tumors. Cell Res 16: 241-259. 
141 
 
29.  Wang Q, You T, Yuan D, Han X, Hong X, et al. (2010) Cisplatin and oxaliplatin inhibit 
gap junctional communication by direct action and by reduction of connexin expression, 
thereby counteracting cytotoxic efficacy. J Pharmacol Exp Ther 333: 903-911. 
30.  He B, Tong X, Wang L, Wang Q, Ye H, et al. (2009) Tramadol and flurbiprofen depress 
the cytotoxicity of cisplatin via their effects on gap junctions. Clin Cancer Res 15: 5803-
5810. 
31.  Boyle RG,Travers S (2006) Hypoxia: targeting the tumour. Anticancer Agents Med Chem 
6: 281-286. 
32.  Kawase M,Motohashi N (2003) New multidrug resistance reversal agents. Curr Drug 
Targets 4: 31-43. 
33.  Walker PR, Smith C, Youdale T, Leblanc J, Whitfield JF, et al. (1991) Topoisomerase II-
reactive chemotherapeutic drugs induce apoptosis in thymocytes. Cancer Res 51: 1078-
1085. 
34.  Story MD, Stephens LC, Tomasovic SP, Meyn RE (1992) A role for calcium in regulating 
apoptosis in rat thymocytes irradiated in vitro. Int J Radiat Biol 61: 243-251. 
35.  Ramadoss P, Marcus C, Perdew GH (2005) Role of the aryl hydrocarbon receptor in drug 
metabolism. Expert Opin Drug Metab Toxicol 1: 9-21. 
36.  Okey AB, Riddick DS, Harper PA (1994) The Ah receptor: mediator of the toxicity of 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and related compounds. Toxicol Lett 70: 1-
22. 
37.  Chang JT, Chang H, Chen PH, Lin SL, Lin P (2007) Requirement of aryl hydrocarbon 
receptor overexpression for CYP1B1 up-regulation and cell growth in human lung 
adenocarcinomas. Clin Cancer Res 13: 38-45. 
 
 
142 
 
Chapter 6 - General Discussions  
Cancer is a disease characterized by deregulated cell proliferation and suppressed cell 
apoptosis. To develop strategy for the prevention and treatment of cancers, it is necessary to 
understand the mechanisms of carcinogenesis. Carcinogenesis is a multi-step, multi-mechanism 
process, which can be divided into at least three steps: initiation, promotion, and progression [1, 
2]. In principle, prevention and treatment of cancer can occur at each step. Avoiding known risk 
factors can prevent cancer initiation but can never reduce the initiation step to zero. Recent 
studies shed some light on the treatment of metastatic cells by uncovering the biological 
mechanisms of cancer cells; however, it is still a big challenge to inhibit the progression step. 
Compared to the initiation and progression steps, promotion step is a reversible and rate limiting 
step of carcinogenesis. Therefore, developing methods to block this step makes the most sense 
[3]. 
Considering GJIC has been linked in normal cells to regulation of growth control, 
differentiation, and apoptosis, it is not surprising that disruption of GJIC is related to 
carcinogenesis. Mounting research indicates that GJIC is involved in every step of 
carcinogenesis, especially in cancer promotion [4]. A wide variety of tumor promoters, such as 
drugs, environmental pollutants, dietary chemicals, heavy metals, natural plant and animal 
toxins, solvents, metabolites, growth factors, hormones, and neurotransmitters, has been shown 
to inhibit GJIC in vitro and/or in vivo [5]. On the contrary, several anti-tumor promoting natural 
and synthetic chemicals have been shown to restore GJIC with the loss of tumorigenicity [5]. In 
addition to the channel activity of GJIC, connexin proteins, especially Cx43, is considered as a 
tumor suppressor in the promotion step. Loss of connexin expression has been observed in most, 
if not all, non-metastatic cancer cells. Over-expression of connexins has been reported to inhibit 
cancer cell proliferation and re-gain the growth control, even though the connexins are failed to 
form gap junctions [6]. Therefore, developing methods or molecules to restore the connexin 
expression and/or the GJIC in the cancer promotion stage is a strategy in cancer treatment.  
PQ1 has been considered as a gap junction enhancer as well as an anti-cancer agent in 
T47D breast cancer cells and xenograft tumors. In the current study, the anti-cancer effect of 
PQ1 was examined in T47D breast cancer cells. T47D is a non-metastatic human breast cancer 
cell line [7]. PQ1 decreased cell viability in a time- and dose-dependent manner, indicating the 
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cytotoxicity of PQ1 on T47D cells. Mechanism studies showed that PQ1 exerted its anti-cancer 
effect by inducing apoptosis through caspase cascade. In the presence of PQ1, both caspase-8, an 
extrinsic apoptotic pathway reporter, and caspase-9, an intrinsic apoptotic pathway reporter, were 
activated, which subsequently activated caspase-3.  
It is not clear that how PQ1 induce the caspase cascade. Krutovskikh et al. have reported 
that GJIC propagates cell death in rat bladder carcinoma BC31 cells by spreading cell-killing 
signals (such as Ca2+) from apoptotic cells to healthy surrounding cells [8]. Because PQ1 is a gap 
junction enhancer which increases GJIC in T47D cells [9], initial hypothesis is that the apoptosis 
induced by PQ1 is related to GJIC. However, later studies provided some evidence that PQ1-
mediated apoptosis is through GJIC-independent pathway. The critical evidence of this effect 
was demonstrated via cell density method. The toxic effect of PQ1 was examined at both high 
cell density and low cell density. At high cell density, there are cell-cell contacts for the 
formation of gap junctions, while at low cell density, few gap junctions could be formed due to 
the lack of cell-cell contacts. Results showed that the cytotoxicity of PQ1 on T47D cells was not 
cell density dependent. Cell viabilities decreased by PQ1 have no significant difference between 
high and low cell density, indicating that the cytotoxicity of PQ1 is GJIC-independent. However, 
the possibility cannot be ruled out that the caspase cascade induced by PQ1 is related to connexin 
via a GJIC-independent mechanism. Expressions of connexins have been reported to be related 
to expressions of apoptotic markers. Using immunohistochemical staining, Kanczuga-Koda et al. 
found the positive correlation between Cx26 and Bax expression, as well as Cx26 and Bcl-XL 
expression in colorectal cancer [10]. The same group also reported a positive correlation between 
Cx26 and Bak expression, as well as between Cx43 and Bak, but not between connexins and 
Bcl-2 in breast cancer [11]. The associations between connexin expression and apoptotic marker 
expression suggest that connexins might be a target for modulations of apoptosis. PQ1 has been 
shown to increase expressions of Cx26, Cx32, and Cx43 in T47D cells [12]. Studies of intrinsic 
apoptotic pathway showed that PQ1 increased expression of Bax, but had no effects on the 
expression of Bcl-2. Based on all the studies, one explanation of PQ1 induced apoptosis is that 
PQ1 over-expresses connexins which modulate the caspase cascade via a channel activity 
independent mechanism.  
Another explanation is related to the chemical structure of PQ1. PQ1 is a quinoline 
derivative. Many quinoline derivatives have been reported as DNA intercalators with the abilities 
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to induce apoptosis in cancer cells. For example, the quinoline derivative, 8-methoxy 
pyrimido[4’,5’:4,5]-,50:4,5]thieno (2,3-b)quinoline-4(3H)-one (MPTQ), has been reported to 
induce the activation of  caspase-3 through both intrinsic and extrinsic pathways [13]. MPTQ has 
a small alkyl methoxy group and the substituted oxygen in the aromatic ring that may facilitate 
its entry into the cells [13]. After entering the cells, MPTQ has been shown to intercalate into 
double-stranded DNA, as well as induce intracellular reactive oxygen species (ROS), which 
subsequently affect major physiological functions [13]. Similar to MPTQ, PQ1 has a small alkyl 
methoxy group in the aromatic ring. Therefore, the second explanation of PQ1 induced apoptosis 
is that after entering the cells with the help of methoxy group, PQ1 intercalates into DNA or 
interacts with regulatory proteins, which may cause DNA-strand breaks, cytokinesis disruptions, 
and apoptosis. More studies are needed to figure out which explanation is correct.  
In addition to the anti-cancer effect, the interest with PQ1 may be its function on gap 
junctions, which is distinct from other quinoline derivatives with anti-cancer effects. PQ1 acts as 
a gap junction enhancer by increasing GJIC in T47D cells [9]. The main strategy in GJIC-based 
cancer therapies relied on bystander effect. Therefore, combinational effect of PQ1 and cisplatin 
was examined in T47D cells to evaluate the bystander effect induced by PQ1. Cisplatin is a 
common used anti-cancer drug. Cisplatin-induced cytotoxicity has been reported to be 
transduced to neighboring cells through GJIC [14]. Recent studies showed that cisplatin inhibits 
GJIC by direct decrease of channel activity and by reduction of connexin expressions, thereby 
counteracting its cytotoxic efficacy [15]. Therefore, one of the strategies to potentiate cisplatin 
effect is increase of GJIC. Studies showed that combinational treatment with PQ1 and cisplatin 
counteracted cisplatin reduction of  GJIC and connexin expressions, thus increasing cytotoxic 
effects on T47D cells [12]. Consisting with previous reports, the cytotoxicity of combinational 
treatment was greater at high cell density with cell-cell contacts of gap junction formation, 
indicating that GJIC is an important factor involved in the enhancement of cytotoxic effects [12]. 
Further studies would be required to identify the toxic molecules or signals that transmitted from 
target cells to neighboring cells via GJIC in the combinational treatment. Overall, the 
combinational study suggests that PQ1 as a gap junction enhancer can be used to potentiate 
efficacy of anti-cancer drugs.  
Prior to the transition from basic research of drug development to translation medicine, a 
major concern of anti-cancer drugs is the side-effect, an adverse effect resulted from damage to 
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normal cells. In the previous study, minimal toxicity of PQ1 on normal human mammary 
epithelial cells (HMECs) was observed within the effective doses of anti-cancer effects and 
GJIC-mediated responses [9]. Compared to controls, treatment of 200 nM PQ1 has 67% cell 
viability in T47D cells, but has 103% cell viability in HMECs [9]. Based on this study, the 
effects of PQ1 on normal organs were evaluated in healthy C57BL/6J mice via oral 
administration. Results showed that PQ1 can be absorbed, distributed to vital organs, and 
diminished after 24 hours [16]. In most, if not all, tested organs, PQ1 increased the expression 
level of anti-apoptotic marker, survivin, while decreased the expression levels of pro-apoptotic 
markers, cleaved caspase-3 and caspase-8 [16]. In the organs with Cx43, the expression of Cx43 
was decreased in the presence of PQ1 [16]. No histological changes were observed after PQ1 
treatment [16]. All these results suggest that PQ1 administration by oral gavage can be achieved 
with low toxicity to normal vital organs. It is very interesting that PQ1 has opposite effects on 
apoptosis in normal organs and cancer cells. The causes of PQ1 opposing effects are not clear. 
Because PQ1 up-regulates Cx43 in cancer cells while down-regulates Cx43 in normal organs, a 
possibility is that PQ1 acts as a modulator of connexin expression and subsequently mediates 
apoptosis. More studies are needed to identify the primary molecular targets or signaling 
pathways that are involved in the PQ1-induced regulation of connexin expressions.  
Overall, studies in this dissertation have provided information that PQ1 is an effective 
tool to enhance GJIC in combinational chemotherapy, as well as a promising anti-cancer 
candidate for drug development due to its high cytotoxicity on cancer cells and low toxic effects 
on normal organs.  
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